|Drug, bio-affecting and body treating compositions patents - Monitor Patents|
USPTO Class 424 | Browse by Industry: Previous - Next | All
10/2009 | Recent | 13: May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Drug, bio-affecting and body treating compositions October categorized by USPTO classification 10/09Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 10/30/2009 > patent applications in patent subcategories. categorized by USPTO classification
10/23/2009 > patent applications in patent subcategories. categorized by USPTO classification
10/15/2009 > patent applications in patent subcategories. categorized by USPTO classification
20090257949 - Radiopharmaceutical imaging of neurodegenerative diseases: Methods for simultaneously detecting dementia or cognitive impairment, such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Lewy Body Dementia (LBD) and Vascular Dementia (VaD) in a patient using dual or multiple radiopharmaceutical probes are provided herein.... Agent: Pepper Hamilton LLP
20090257952 - Engineered integrin binding peptides: Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (α5β1) or vitronectin (αvβ3 and αvβ5 integrins) are disclosed. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence... Agent: Peters Verny , L.L.P.
20090257950 - Membrane scaffold proteins: The membrane scaffold proteins (MSP) of the present invention assemble with hydrophobic or partially hydrophobic proteins to form soluble nanoscale particles which preserve native structure and function; they are improved over liposomes and detergent micelles, both in terms of stability and preservation of biological activity and native conformation. In the... Agent: Greenlee Winner And Sullivan P C
20090257951 - Ngr receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same: The present invention provides a method of identifying a tumor homing molecule that homes to angiogenic vasculature by contacting a substantially purified NGR receptor with one or more molecules and determining specific binding of a molecule to the NGR receptor, where the presence of specific binding identifies the molecule as... Agent: Mcdermott, Will & Emery
20090257953 - Novel fluorine-18 labeled rhodamine derivatives for myocardial perfusion imaging with positron emission tomography: The present invention is directed toward novel fluorine-18 labeled rhodamine dye derivatives and methods of making the same. The present invention is also directed toward methods of using novel fluorine-18 labeled rhodamine dye derivatives as positron emission tomography imaging agents and myocardial perfusion imaging agents.... Agent: David S. Resnick
20090257954 - Development of a simple animal model for infection by viruses and other obligate intracellular parasites: The present invention provides methods for studying pathogenesis of mammalian viruses. In particular, the present invention provides a nonhuman animal model system for studying disease mechanisms wherein the nonhuman animal model is infected with an animal virus. In a preferred embodiment the animal model is C. elegans and the animal... Agent: Angela Foster, Phd, Esq.
20090257955 - Sheep model of neuropathic pain behavior and uses thereof: Methods for producing peripheral nerve injury in sheep are provided. The sheep model provides a model of persistent neuropathic pain in humans. Methods for drug delivery are provided. Also provided is a method for screening potentially therapeutic agent for the treatment of persistent neuropathic pain. Also provided are the methods... Agent: Benjamin Aaron Adler Adler & Associates
20090257956 - Treatment method for treatment of erectile dysfunction and premature ejaculation: A method for a same visit treatment for erectile dysfunction and premature ejaculation. The method includes: performing a diagnostic on the patient using physical conditions of the patient; determining a diagnostic group of the patient, wherein each diagnostic group has corresponding conditions to the physical conditions of the patient; identifying... Agent: Baker & Hostetler LLP
20090257957 - Aerosolized lfa-1 antagonists for use in localized treatment of immune related disorders: This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for aerosolized delivery. In particular, the LFA-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders... Agent: Wilson, Sonsini, Goodrich & Rosati
20090257958 - Pesticidal compositions: The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to a pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations.... Agent: Patent Docket Department Armstrong Teasdale LLP
20090257959 - Pesticidal compositions: The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to a pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations.... Agent: Patent Docket Department Armstrong Teasdale LLP
20090257960 - Neutralized acid group-containing polymers and the use thereof: The present invention relates to a polymer component which consists of one polymer or of a plurality of different polymers, comprises at least one polyurethane, where the polymer or at least one of the polymers has acid groups which are neutralized partially with at least one inorganic base and partially... Agent: Connolly Bove Lodge & Hutz LLP
20090257961 - Denture care composition: This invention relates to a new denture care composition and method of use. In particular, this invention relates to a film-forming denture care composition that kills odor causing bacteria, maintains prolonged fresh breath for two or more hours and is an effective guard against denture odor.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220
20090257962 - Compositions for human dental care: Compositions of the invention are water-based formulas that contain natural ingredients which aid in reduction of bacteria in the mouth, thereby reducing plaque and the production of tartar, and in one aspect of the invention are formulated as potable dental water that may be consumed in place of regular consumption... Agent: Morriss Obryant Compagni, P.C.
20090257964 - Fluoride-releasing strips for caries prevention: The present invention discloses fluoride-releasing strips for caries prevention, wherein the fluoride-releasing strips comprises a colloidal fluoride-containing solution for releasing fluorine ion and a support substrate. A colloidal fluoride-containing solution comprises a fluoride solution, at least one buffer, at least one moisturizer and a carboxymethyl cellulose (CMC). The concentration of... Agent: Wpat, PC
20090257963 - Method for measurably improving oral health: A composition for measurably improving oral health, a system including the composition, a method of using the composition and system, and a method of forming the composition and system are disclosed. The composition is a gel that maintains contact with a portion of an oral cavity for an extended period... Agent: Snell & Wilmer L.L.P. (main)
20090257965 - Abnormal protein removing composition: Provide an effective composition for removing abnormal protein. Also, a composition for removing abnormal protein whose main ingredient is soyasaponin B group, which is used to provide a composition, agent or food contributing to the prevention or treatment of diseases caused by proteolysis abnormality, among others.... Agent: Knobbe Martens Olson & Bear LLP
20090257966 - Ternary and quaternary wax-resin composites for use in cosmetic and pharmaceutical preparations: A wax-resin composite is made by melting thermoplastic hydrocarbon resin, optionally with an antioxidant. The melted thermoplastic hydrocarbon resin and waxes are blended at a temperature sufficient to melt the waxes. After blending and melting, the blended thermoplastic hydrocarbon resin and waxes are allowed to solidify. Solidification is followed by... Agent: Thompson Hine L.L.P. Intellectual Property Group
20090257967 - Compositions comprising sugar beet pectin and carotenoids: Carotenoid compositions for use as colorants or additions for food, animal feeds, cosmetics or drugs comprise finely dispersed carotenoids in a sugar beet matrix.... Agent: Stephen M. Haracz, Esq. Bryan Cave LLP
20090257968 - Gels containing anionic surfactants and coupling agents: The present invention provides an enhanced gelling agent composition comprising a mixture of an anionic surfactant and a coupling agent. The invention also describes compositions in gel form comprising: (a) a solvent selected from the group consisting of polar solvents, non-polar solvents and combinations thereof; and (b) a gelling agent... Agent: Isaac A. Angres
20090257969 - Soft anticholinergic zwitterions: e
20090257970 - Antiperspirant compositions containing a copper salt and a penetration enhancer and methods of using the same: Antiperspirant compositions including a copper salt and a penetration enhancer are described. The penetration enhancer may be salicylic acid or urea. In addition to a copper salt, the composition may also comprise an aluminum or zirconium salt. Methods of using the compositions are also described. Embodiments may be useful in... Agent: Lawrence F. Rozsnyai
20090257971 - Antiperspirant composition: An antiperspirant composition with the antiperspirant composting containing a thickening agent in sufficient quantity so as to produce an antiperspirant composition wherein the viscosity is less than 2400 centpoises.... Agent: Jacobson & Johnson
20090257972 - Cosmetic and dermatological compositions in particular for the treatment of keratin containing substrates: The present invention relates to cosmetic and/or dermatological compositions for the treatment of keratin containing substrates, comprising synergistic mixtures of modified starch polymers with defined molecular weights and cationic charges in a cosmetically acceptable medium. The synergistic mixtures of modified starches employed to manufacture compositions according to the present invention... Agent: Roberts & Roberts, LLP Attorneys At Law
20090257973 - Malodor reducing composition, fragrance composition and product comprising the same: wherein R4, R5 and R7 are each independently, a C1-C5 linear or branched alkyl or alkenyl group, R6 is a (C1-C5) alkylidene, R4 and R5 may form a C4-C7 saturated or unsaturated alicyclic or hetrocyclic ring structure which may be mono-substituted or poly-substituted by (C1-C4) alkyl groups, and R6 and... Agent: Sughrue-265550
20090257974 - Perfume compositions: Perfume compositions comprise between 10% and 30% in total by weight of perfume ingredients selected from two groups, Group A, Group B, with the provisos that over 5% but less than 15% of the perfume composition must comprise Group A ingredients, and for compositions comprising less than 10% of Group... Agent: Norris, Mclaughlin & Marcus
20090257975 - Solid and semi-solid polymeric ionic conjugates: Aqueous solubility of drugs including insoluble or poorly soluble drugs such as ziprasidone is improved using a functional polymer to form an ionic conjugate with said drug.... Agent: Pfizer Inc. Patent Department
20090257976 - Single vial formulation for medical grade cyanoacrylate: Alkyl cyanoacrylate compositions and methods for making those compositions, utilizing high purity monomeric starting materials, formed into more viscous oligomers, and combined with a plasticizer and inhibitor to provide a single-container, storage stable medical cyanoacrylate.... Agent: Knobbe Martens Olson & Bear LLP
20090257977 - Novel tetrahydropyridothiophenes: Compounds of a certain formula (I), in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.... Agent: Millen, White, Zelano & Branigan, P.C.
20090257978 - Antiviral coumpounds: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Gilead Sciences Inc
20090257980 - Anti-virus therapy for respiratory diseases: The present invention provides the use of IFN-β, an agent that increases the expression of IFN-β, or a polynucleotide which is capable of expressing IFN-β or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive... Agent: Morrison & Foerster LLP
20090257979 - Novel inhibitors of hepatitis c virus replication: The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in... Agent: Knobbe Martens Olson & Bear LLP
20090257982 - medical device for treating diabetes mellitus, obesity, chronic fatigue, aging, and other medical conditions by utilizing modified virus virions to insert messenger ribonucleic acid molecules into cells: The common link between diabetes mellitus, obesity, chronic fatigue and even aging may be related to deficiencies involving a body's metabolism of glucose and the ability to optimally conduct the necessary biologic processes of aerobic respiration. Utilizing a medical device comprised of a modified form of virus to deliver to... Agent: Lane B. Scheiber
20090257983 - Medical treatment device for treating aids by utilizing modified human immunodeficiency virus virions to insert anti-viral medications into t-helper cells: The medical device by which a modified Human Immunodeficiency Virus or virus-like structure is used as a transport medium to carry a payload of a quantity of anti-viral drug molecules to T-Helper cells in the body. The modified Human Immunodeficiency Virus or virus-like structure makes contact with a T-Helper cell... Agent: Lane B. Scheiber
20090257981 - Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same: Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20090257991 - Engineering and delivery of therapeutic compositions of freshly isolated cells: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered... Agent: Fulbright & Jaworski L.L.P.
20090257990 - Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues: Polynucleotide expression constructs, populations of cells and methods of treating diseases caused by dysfunction in, or damage to, excitable tissues are provided.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.
20090257992 - Adjunctive agent for lavaging the alimentary canal comprising butyric acid bacterium and/or lactic acid bacterium: The present invention provides an adjunctive agent for lavaging the alimentary canal which is able to reduce a dose of oral cleaning agent for lavaging the alimentary canal, and is capable of realizing an excellent cleaning effect at the time of use of the aforementioned oral cleaning agent for lavaging... Agent: Fox Rothschild LLP Princeton Pike Corporate Center
20090257993 - Lactic acid producing bacteria and lung function: The present invention provides novel use for live (probiotic) lactic acid producing bacteria, dead or non-viable bacteria thereof, as well as food supplements, nutritive compositions and/or pharmaceutical compositions comprising these, for the treatment or prophylaxis of lung dysfunction in a subject. A suitable lactic acid producing bacterium has a significant... Agent: Jay S Cinamon Abelman, Frayne And Schwab
20090257995 - Harmful bacterium control agent containing bacillus thuringiensis: Through inhibition of the multiplication of pathogenic bacteria and inactivation of bacterial self-induced factors, the balance of intestinal flora is improved to thereby promote regulation of animal intestinal functions and enable prevention/treatment of infection disease caused by such pathogenic bacteria. Accordingly, a pharmaceutical containing Bacillus thuringiensis is administered to animals,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20090257984 - Antifungal compositions containing the endophyte fungus alternaria alternata and or its metabolites, as antagonist agents of plasmopara viticola: The present invention relates to compositions containing the fungus Alternaria alternata and/or the secondary metabolites thereof, which belong to the family of the diketopiperazines (DKPs), for controlling the pathogen fungus Plasmopara viticola.... Agent: Nixon & Vanderhye, PC
20090257986 - Epidermal and dermal equivalents: The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood... Agent: Fulbright & Jaworski L.L.P.
20090257989 - Intraperitoneal delivery of genetically engineered mesenchymal stem cells: A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells genetically engineered with at least one polynucleotide encoding the at least one protein. The method may be employed in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia,... Agent: Mcandrews Held & Malloy, Ltd
20090257987 - Method of generating dopamine-secreting cells: Methods of generating cells which secrete dopamine are disclosed. One method comprises incubating mesenchymal stem cells in a culture medium comprising brain derived neurotrophic factor (BDNF), wherein the culture medium comprises no more than 0.1 μM retinoic acid (RA). Another method comprises incubating mesenchymal stem cells in a culture medium... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.
20090257988 - Methods and compositions for accelerating the generation of regulatory t cells ex vivo: The present invention is directed to generating regulatory T cells by treating a cell culture that includes non-regulatory T cells with a regulatory composition. The invention encompasses methods utilizing a regulatory composition that includes agents that prevent methylation of the locus for the FOXP3 transcription factor, agents that accelerate differentiation... Agent: Morgan, Lewis & Bockius, LLP
20090257985 - Methods of regulating expression of genes or of gene products using substituted tetracycline compounds: The present invention relates, at least in part, to the use of substituted tetracycline compounds for regulation of expression of nucleic acids operably linked to a tetracycline operator system. The invention pertains to compounds used in a regulatory system which utilizes components of the Tet repressor/operator/inducer system of prokaryotes to... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c
20090257994 - Chimeric immunoreceptor useful in treating human cancers: The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.
20090257996 - Dietary supplement energy-providing to skeletal muscles and protecting the cardio vascular tract: Dietary supplements—providing energy and strengthening skeletal muscles and facilitating skeletal muscles ability to sustain prolonged periods of physical activity—containing propionyl-L-carnitine or one of its salts, coenzyme Q10, nicotinamide, riboflavin, pantothenic acid and optionally other components such as amino acids and creatines.... Agent: Lucas & Mercanti, LLP
20090257997 - Stable aqueous compositions comprising bioactive creatine species: Compositions containing one or more bioactive forms of creatine which are aqueous compositions in which the one or more bioactive forms of creatine do not appreciably degrade into creatinine. Also are methods for providing various beneficial effects which comprise administering aqueous compositions comprising at least one creating O-phosphate species to... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20090257998 - Method for treating heart attacks, strokes and diabetic crisis by utilizing modified virus virions to insert necessary protein molecules and vital nutrients into targeted cells: The common link between incurring a heart attack, suffering a stroke or diabetic crisis is related to deficiencies involving a body's metabolism of glucose and the ability to optimally conduct the necessary biologic processes of aerobic respiration to produce energy molecules. Utilizing a medical treatment method comprised of a modified... Agent: Lane B. Scheiber
20090257999 - Method of preventing contrast-induced nephropathy: The present invention relates to methods of preventing contrast-induced nephropathy including the step of administering an effective amount of a compound (e.g., a peroxynitrite decomposition agent, a PARP inhibitor or a superoxide dismutase mimic) to a subject to be administered a contrast agent.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000
20090258000 - Mucosally non-irritative amphotericin b formulations and methods for treating non-invasive fungus-induced mucositis: The present invention is directed to compositions and methods for non-irritatively treating and preventing non-invasive fungus-induced mucositis. Specifically, the invention involves compositions including a mucosally non-irritative mixture of amphotericin B and a pharmaceutically acceptable carrier. Such compositions can be non-irritatively mucoadministered to prevent, reduce, or eliminate chronic non-invasive fungus-induced mucositis... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20090258001 - Administration of anti-cd3 antibodies in the treatment of autoimmune diseases: A method of treating an autoimmune disease, such as, diabetes or psoriasis, by administering an anti-CD3 antibody, or anti-CD3 antibody fragment. The anti-CD3 antibody, or antibody fragment, is administered over a course of treatment wherein, during the course of treatment, the anti-CD3 antibody, or anti-CD3 antibody fragment is administered in... Agent: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein
20090258002 - Biomarkers for tissue status: The invention relates to methods of accurately and quickly diagnosing and monitoring the progression of cancer and ischemally injured tissue. The invention also provides methods of treatment as well as methods of screening for compositions useful for treating the disorders.... Agent: Edwards Angell Palmer & Dodge LLP
20090258003 - Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular VT and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for... Agent: Celera Corporation
20090258004 - Human blood proteins expressed in monocot seeds: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, and to methods of making these isolated blood proteins and to therapeutic compositions comprising them.... Agent: Arent Fox LLP
20090258006 - Method of modulating neovascularization: The invention provides a method of inhibiting neovascularization in a subject. The method comprises administering to the subject an agent that interferes with fibronectin (Fn) matrix assembly in an amount effective to inhibit neovascularization. The invention also provides a method of identifying an agent that inhibits neovascularization. The method comprises... Agent: Marshall, Gerstein & Borun LLP
20090258005 - Therapeutic compositions and methods: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.... Agent: Ropes & Gray LLP
20090258007 - Anti-perp antibody: The present invention provides an antibody which specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by PERP (p53 apoptosis effector related to PMP-22) gene and binds to the extracellular region. The antibody of the present invention is useful for treatment of various diseases which highly expresses... Agent: Sughrue Mion, PLLC
20090258011 - Antibodies against west nile virus and therapeutic and prophylactic uses thereof: The present invention relates to compositions comprising antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV), and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV), infection utilizing said compositions.... Agent: Drinker Biddle & Reath (dc)
20090258014 - Combination of hgf inhibitor and egf inhibitor to treat cancer: The present invention is directed toward a method of treating cancer by administering to a patient an inhibitor of Hepatocyte Growth Factor and an inhibitor of, e.g., Epidermal Growth Factor.... Agent: Townsend And Townsend And Crew, LLP
20090258012 - Compositions and methods for treating inflammatory disorders: The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.... Agent: Edwards Angell Palmer & Dodge LLP
20090258010 - Methods, compositions, and kits for treating shiga toxin associated conditions: The invention features methods, compositions, and kits for treating a subject having a Shiga toxin associated disease with chimeric anti-Shiga Toxin 1 (cαStx1) and anti-Shiga Toxin 2 (cαStx2) antibodies.... Agent: Clark & Elbing LLP
20090258015 - Modulators of candida hyphal morphogenesis and uses thereof: The invention relates to modulation of fungal morphology between yeast-to-hyphal growth transition by controlling muramyl-L-alanine concentration and uses thereof.... Agent: Cohen, Pontani, Lieberman & Pavane LLP
20090258013 - Novel compositions and methods for the treatment of immune related diseases: The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Genentech, Inc.
20090258009 - Protofibril selective antibodies and the use thereof: The present invention pertains to the prevention, treatment and diagnosis of neurodegenerative diseases, in particular Alzheimer's disease, and other similar disease. More specifically to high affinity antibodies selective for amyloid beta protein (Aβ) in its protofibril conformation and of IgG class and IgG1 or IgG4 subclass or combinations thereof or... Agent: Clark & Elbing LLP
20090258016 - Substituted imidazole derivatives: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:... Agent: Novartis Institutes For Biomedical Research, Inc.
20090258008 - Uses of the fcrn receptor: The invention relates to the field of biochemistry and molecular biology. More specifically the invention relates to the production of (monoclonal) antibodies and even more specifically to the production of therapeutic and diagnostic antibodies. The invention provides a method for producing an antibody or a functional part, derivative and/or analogue... Agent: Traskbritt, P.C.
20090258017 - Lyophilized therapeutic peptibody formulations: The present invention provides long-term stable formulations of a lyophilized therapeutic peptibody and methods for making a lyophilized composition comprising a therapeutic peptibody.... Agent: Amgen Inc.
20090258018 - Methods for treating juvenile idiopathic arthritis: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for... Agent: Lahive & Cockfield, LLP/abbott Floor 30, Suite 3000
20090258019 - Diagnosis of carcinoma using raig1 polypeptides: The present invention relates to the new uses of a polypeptide (retinoic acid-inducible gene 1; RAIG1, also known as hypothetical protein FLJ10899 or retinoic acid induced 3) compositions comprising the polypeptide, including vaccines, antibodies that are immunospecific for the polypeptide and agents which interact with or modulate the expression or... Agent: Klauber & Jackson
20090258020 - Antibody designated barb3, barb3 related antibodies, and methods of making and using same: The invention provides antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions. Antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions are useful in treatment and diagnostic methods. One treatment method includes inhibiting growth or proliferation of proliferating cells, such as hyperproliferative cells or... Agent: Pillsbury Winthrop Shaw Pittman LLP
20090258022 - Antibodies to brain specific membrane protein: A novel gene apparently encoding a transmembrane glycoprotein has been successfully isolated by constructing a cDNA library of 4 kb or above in size from mRNA expressed in human adult brain and analyzing the structures of the cDNAs contained within said library by the shotgun method. The novel gene shows... Agent: Fish & Richardson PC
20090258021 - Genes associated with mechanical stress, expression products therefrom, and uses thereof: The disclosure relates to human and mechanical stress induced genes, in particular gene 608, and functional equivalents, probes therefor, tests to identify such genes, polypeptide expression products of such genes, antibodies to the polypeptides, uses for such genes, expression products and antibodies, e.g., in diagnosis (for instance risk determination), treatment,... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw
20090258023 - Tgf-beta superfamily binding proteins and modulation of bone formation and loss: The present invention relates to novel polynucleotides and polypeptides that are expressed in osteoblasts, interact with members of the TGF-β superfamily, and inhibit mineralization. The invention further relates to the use of these polynucleotides and polypeptides to modulate bone formation and bone loss.... Agent: Myers Bigel Sibley & Sajovec
20090258024 - Compositions and methods for diagnosis and treatment of chronic inflammatory diseases: This invention relates to methods and compositions for diagnosis and treatment of chronic inflammatory diseases by blocking CD147 interaction with extracellular cyclophilin. Specifically, the methods and compositions of this invention regulate recruitment of leukocyte to the infection site by specifically blocking the CD147 domain involved with the chemotactic function without... Agent: Law Offices Of Khalilian Sira, LLC
20090258025 - Treatments and diagnostics for cancer, inflammatory disorders and autoimmune disorders: Methods for the treatment of cancer with therapies targeting tumor-associated macrophage activities are provided. Methods for the treatment of cancer, inflammatory and autoimmune disorders with therapies using tumor-associated macrophages and adipose tissue macrophages are also provided.... Agent: Genentech, Inc.
20090258026 - Anti-notch1 nrr antibodies and methods using same: The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies.... Agent: Clark & Elbing LLP
20090258027 - Methods of modulating immune function: The invention relates to methods for modulating the immune function through targeting of CLIP molecules as well as gamma delta T cells. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease,... Agent: Wolf Greenfield & Sacks, P.C.
20090258028 - Methods of forming coatings for implantable medical devices for controlled release of a peptide and a hydrophobic drug: This invention is generally related to methods of forming coatings for implantable medical devices, such as drug delivery vascular stents. The methods are for forming coatings to control the release of a peptide such as RGD, and a hydrophobic drug. Both single layer and multiple layer coating constructs are encompassed... Agent: Squire, Sanders & Dempsey LLP
20090258029 - Heparin prodrugs and drug delivery stents formed therefrom: A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a... Agent: Squire, Sanders & Dempsey LLP
20090258030 - Materials and methods for improving livestock productivity: The subject invention provides methods for improving livestock health. In specific embodiments, the invention provides methods for accelerating and/or augmenting livestock growth; improving immunity; and enhancing fertility in livestock. To do so, the present invention provides materials and methods for administering a cysteamine compound to livestock.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20090258031 - Immunosuppressive polypeptides and nucleic acids: The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided.... Agent: Maxygen, Inc. Intellectual Property Department
20090258032 - Methods and compositions targeting viral and cellular itam motifs, and use of same in identifying compounds with therapeutic activity: This invention provides methods of treating, reducing the incidence of, and inhibiting metastasis formation of carcinomas, sarcomas, Epstein-Barr virus-induced malignancies, B cell proliferative disorders, and mast cell activation disorders, comprising administering to a subject a compound that inhibits an interaction of a first protein and an immunoreceptor tyrosine-based activation motif... Agent: Pearl Cohen Zedek Latzer, LLP
20090258033 - Hcv e1e2 vaccine compositions: HCV E1E2 compositions comprising E1E2 antigens, submicron oil-in-water emulsions and/or immunostimulatory nucleic acid sequences are described. The compositions can be used in methods of stimulating an immune response in a vertebrate subject.... Agent: Novartis Vaccines And Diagnostics Inc.
20090258034 - Method of inducing mucosal immune response to antigen with dioscorea polysaccharides adjuvant: A method for inducing mucosal immune responses in a subject in need thereof to an antigen includes administering to the subject a vaccine composition including the antigen and a Dioscorea polysaccharides as an adjuvant. Because of the immuomodulatory effect of the Dioscorea polysaccharides, the vaccine composition is further capable of... Agent: Panitch Schwarze Belisario & Nadel LLP
20090258035 - Avian virus vaccines and uses thereof: The present invention relates to poultry vaccines for prevention of Newcastle disease.... Agent: Usda-ars-office Of Technology Transfer Patent Advisors Office
20090258036 - Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3' -utr of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.... Agent: Knobbe, Martens, Olson & Bear, LLP
20090258037 - Vaccine development strategy using microgravity conditions: Methods are provided herein for producing a vaccine, comprising culturing bacteria in microgravity. In some examples, the method includes culturing bacteria in microgravity, evaluating RNA expression, detecting an RNA that is over- or underexpressed during culture in microgravity, deleting the over- or underexpressed RNA in bacteria, and killing or attenuating... Agent: Klarquist Sparkman, LLP
20090258039 - Method of administering a pharmaceutical active ingredient: A method for reducing the friability of soft substrates by applying an effective amount of a water soluble, polymeric dispersion to at least a portion of a treatment surface of the substrate, such that less than about 90% of the exterior surface has the dispersion applied thereto.... Agent: Philip S. Johnson Johnson & Johnson
20090258040 - Steroid treatment for hot flashes: Embodiments of the invention relate to methods for treating individuals suffering from hot flashes by vomeronasally administering a therapeutically effective dosage of a steroid agent. The hot flashes may be a result of postmenopause or castration suffered by the individual. In many embodiments, the method for treating individuals suffering with... Agent: Patterson & Sheridan, L.L.P.
20090258038 - Water-soluble compositions of bioactive lipophilic compounds: wherein: X is a residue of a hydrophobic moiety, Y is a residue of a hydrophilic moiety, p is 1 or 2, m is 0 or 1, and n is an integer greater than or equal to 0 are disclosed. The lipophilic compound is preferably selected from the group consisting... Agent: Morgan, Lewis & Bockius LLP (sf)
20090258043 - Dispersions comprising acylglutamates: The invention relates to dispersions comprising water, lipophilic phase and emulsifier, characterized in that the emulsifier is present in an amount of less than or equal to 3% by weight based on the total weight of the dispersion, and in that the emulsifier comprises at least one acylglutamate. The dispersions... Agent: Fox Rothschild LLP
20090258042 - Encapsulated active materials containing adjunct crosslinkers: It is an object of the present invention to provide a microcapsule product comprising an active material; said active material encapsulated by a polymeric material to provide a polymer encapsulated material wherein said polymeric material comprises an adjunct crosslinker.... Agent: International Flavors & Fragrances Inc.
20090258041 - Protection of oxidizable agents: Formulations for cosmetical or pharmaceutical use contain an antioxidant in encapsulated form and a cosmetically or pharmaceutically acceptable carrier. The antioxidant is selected from carbon bridged hindered phenoles, ester bridged hindered phenoles, amide bridged hindered phenoles, lactones of hindered phenoles, sterically hindered oxylamines and sterically hindered hydroxylamines. The encapsulated antioxidant... Agent: Joann Villamizar Ciba Corporation/patent Department
20090258044 - Kit for insect bites: A travel kit used for inhibiting and reducing the incidence and effect of insect bites. The kit includes a pouch for enclosing a plurality of containers therein. The pouch has a closure means to maintain the containers in the pouch and a means for removably attaching the pouch to a... Agent: Michael E. Zall
20090258045 - Structures including antimicrobial peptides: A structure includes a substrate and a first plurality of bilayers on the substrate. The first plurality of bilayers includes a first layer including an antimicrobial peptide having a charge, and a second layer including a polyelectrolyte having a charge opposite the charge of the first layer. At least a... Agent: Choate, Hall & Stewart LLP
20090258046 - Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent: A pharmaceutical or veterinary composition, which comprises a first active agent selected from a non-glucocorticoid steroid or analogues, a ubiquinone, or salts thereof, and a second active agent comprising a bronchodilator. The composition is provided in various formulations and in the form of a kit. The products of this patent... Agent: Wilson, Sonsini, Goodrich & Rosati
20090258047 - Heparin prodrugs and drug delivery stents formed therefrom: A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a... Agent: Squire, Sanders & Dempsey LLP
20090258052 - Compounds and methods for altering bone growth: p
20090258050 - Controlled drug delivery using a zein layer modified with levulinic acid: The disclosure relates to medical devices coated with zein admixed with levulinic acid. The medical device may further include a therapeutic agent in contact with zein admixed with levulinic acid. Zein admixed with levulinic acid allows the therapeutic agent to be retained on the device during delivery and also controls... Agent: Brinks Hofer Gilson & Lione/chicago/cook
20090258049 - Drug eluting expandable devices: The present disclosure relates to drug eluting devices, and their uses. The drug eluting devices can allow for perfusion during deployment. The coatings the may contain bioactive materials which elute once deployed in a patient and can have anti-proliferative, anti-inflammation, or anti-thrombotic effects. Sol gel technology can be used to... Agent: K&l Gates LLP Attn: Michelle S. Glasky, Ph.d.
20090258054 - Heparin prodrugs and drug delivery stents formed therefrom: A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a... Agent: Squire, Sanders & Dempsey LLP
20090258055 - Heparin prodrugs and drug delivery stents formed therefrom: A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a... Agent: Squire, Sanders & Dempsey LLP
20090258053 - Medical stent provided with a combination of melatonin and paclitaxel: A stent provided with a composition comprising melatonin and paclitaxel is described. The described stent is useful in treating smooth muscle cell proliferation, such as stenosis and preventing restenosis in vascular vessels.... Agent: Knobbe Martens Olson & Bear LLP
20090258051 - Microbes encapsulated within crosslinkable polymers: The invention relates to porous films comprising crosslinked electrospun hydrogel fibers. Viable microbes are encapsulated within the crosslinked electrospun hydrogel fibers. The crosslinked electrospun hydrogel fibers are water insoluble and permeable. The invention also relates to methods of making and using such porous films.... Agent: Brookhaven Science Associates/ Brookhaven National Laboratory
20090258048 - Self-assembling monomers and oligomers as surface-modifying endgroups for polymers: Polymers having the formula R(LE)x wherein R is a polymeric core having a number average molecular weight of from 5000 to 7,000,000 daltons and having x endgroups, E is an endgroup covalently linked to polymeric core R by linkage L, L is a divalent oligomeric chain, having at least 5... Agent: Birch Stewart Kolasch & Birch
20090258056 - Systems and methods for preparing autologous fibrin glue: A method of regenerating tissue in a living organism. The method includes the act of contacting an affected area of the living organism with a solid-fibrin web, the solid-fibrin web comprising platelets that release growth factors about one minute after contact to regenerate the tissue in the living organism.... Agent: Michael Best & Friedrich LLP
20090258057 - Synthetically functionalized living cells: Uniform, functional polymer patches can be attached to a fraction of the surface area of living individual cells. These surface-modified cells remain viable after attachment of the functional patch. The patch does not completely occlude the cellular surface from the surrounding environment. Functional payloads carried by the patch may include,... Agent: Steptoe & Johnson LLP
20090258058 - Novel silicone film former for delivery of actives: The invention provides: a film-forming composition comprising a) a saccharide-siloxane copolymer; b) a crosslinking agent; c) one or more active/inactive ingredients; and d) optionally, a solvent, or solvent mixture, wherein the saccharide-siloxane copolymer has the following formula: R2aR1(3−a)SiO—[(SiR2R1O)m-(SiR12O)n]y-SiR1(3−a)R2a that is further formulaically defined and wherein the saccharide-siloxane copolymer is a... Agent: Dinsmore & Shohl LLP
20090258059 - Stabilized foam for medical psa substrate: The present invention provides a method for using a stabilized foam that is a crosslinked, closed cell polyolefin having a stabilizing layer and an adhesive layer. The method can be used for treating a wound, scrape, abrasion or skin puncture, for maintaining cleanliness of an operation incision site, suture site,... Agent: Charles N.j. Ruggiero Ohlandt, Greeley, Ruggiero & Perle, L.L.P.
20090258060 - Hydrogel compositions: Hydrogel compositions are provided (a) that have a continuous hydrophobic phase and a discontinuous hydrophilic phase, (b) that have a discontinuous hydrophilic phase and a continuous hydrophilic phase, or (c) that are entirely composed of a continuous hydrophilic phase. The hydrophobic phase, if present, is composed of a hydrophobic polymer,... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c
20090258061 - Once-a-day replacement transdermal administration of fentanyl: A method and a daily replacement patch for transdermally administering an opioid for analgesic effect. The patch is applied to a subject to deliver the opioid through the skin. The patch may be replaced daily and over an extended period of time.... Agent: Stoel Rives LLP - Slc
20090258063 - Transdermal patch: The present invention provides a transdermal patch having excellent preservation stability and transdermal absorbency of DMAEs. The patch has a support and a plaster layer integrally laminated on one surface of the support, and the plaster layer includes: DMAEs; an acrylic adhesive prepared by copolymerizing monomers respectively containing 30 to... Agent: Wenderoth, Lind & Ponack, L.L.P.
20090258062 - Transdermal therapeutic system comprising active ingredient particles and having increased active ingredient flux: The invention relates to a transdermal therapeutic system, preferably a transdermal patch, having an active ingredient-containing matrix formed substantially of a water-insoluble base material, such as rubber and synthetic polymers, into which is incorporated water-soluble and/or water-swellable inclusion bodies, e.g. inclusion bodies formed from polyvinyl alcohol or polyethylene glycol, that... Agent: Propat, L.L.C.
20090258064 - Compositions of ucp inhibitors, fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor: Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a therapeutically acceptable amount of a fatty acid metabolism inhibitor and/or a therapeutically acceptable amount of a glucose metabolism inhibitor, optionally in combination... Agent: Wolf Greenfield & Sacks, P.C.
20090258065 - Dermatological compositions comprising avermectin nanocapsules: Compositions and nanoemulsions containing lipid nanocapsules dispersed in a hydrophilic phase, such nanocapsules including at least one avermectin compound, are useful for the treatment of dermatological pathologies, e.g., rosacea.... Agent: Buchanan, Ingersoll & Rooney PC
20090258066 - Compositions comprising weakly basic drugs and controlled-release dosage forms: The present invention is directed to pharmaceutical compositions, and methods of making such compositions, comprising microparticles containing a weakly basic drug core, a layer of alkaline buffer, and a controlled-release coating. The present invention is also directed to pharmaceutical dosage forms, including orally disintegrating tablets, conventional tablets, and capsules, and... Agent: Cooley Godward Kronish LLP Attn: Patent Group
20090258067 - Modified release composition of at least one form of venlafaxine: The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20090258071 - Compositions and methods for ph targeted drug delivery: The invention provides compositions and methods for the targeted, in particular, pH targeted, delivery of pharmaceutically active agents in mammals. The compositions comprise pH sensitive diblock copolymers, which permit the release of the pharmaceutically active agent when exposed to an environment having a particular pH. The compositions are particularly useful... Agent: Goodwin Procter LLP Patent Administrator
20090258069 - Delivery of lfa-1 antagonists to the gastrointestinal system: The present invention provides compositions and methods for treating disorders and diseases by delivery of LFA-1 antagonists to the gastrointestinal system. Methods include delivery of LFA-1 antagonists to effect localized treatment.... Agent: Wilson, Sonsini, Goodrich & Rosati
20090258072 - Large ultraviolet attenuating pigments: Large particle sunscreen powders useful as ingredients in cosmetic compositions and in dispersions for incorporation into cosmetic compositions comprise a UV shielding agent in a matrix material. The macroparticle powders can be used in a wide range of cosmetic formulations, including sunscreens, eyeshadow, mascara, foundation, blusher, toner, lipstick and other... Agent: Thompson Hine L.L.P. Intellectual Property Group
20090258073 - Magnetic carrier and medical preparation for controllable delivery and release of active substances, methods of their production and methods of treatment using thereof: The present invention relates to magnetic carriers and medical preparations for controllable delivery and release of active substances. The carrier for active substances comprises material A, which is magnetically or electrically sensible, and material B capable of controlling the retention/release rate of the said active substance from the said carrier,... Agent: Dr. Maria Nilova
20090258068 - Titanium oxide-zinc oxide aggregate powder and production method thereof: The present invention provides a powder that can display excellent protection ability in both UV-A and UV-B regions. The titanium oxide-zinc oxide aggregate powder comprises an aggregate formed by the aggregation of porous titanium oxide particles and zinc oxide particles, and said porous titanium oxide particle is an aggregate of... Agent: Rankin, Hill & Clark LLP
20090258070 - Topical lfa-1 antagonists for use in localized treatment of immune related disorders: This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for topical delivery. In particular, the LFA-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders... Agent: Wilson, Sonsini, Goodrich & Rosati
20090258075 - Respiratory drug condensation aerosols and methods of making and using them: Described herein are respiratory drug condensation aerosols and methods of making and using them. Kits for delivering condensation aerosols are also described. The respiratory drug aerosols typically comprise respiratory drug condensation aerosol particles. In some variations the respiratory drug compound is selected from the group consisting of β-adrenergics, methylxanthines, anticholinergics,... Agent: Swanson & Bratschun, L.l.c
20090258076 - Water-soluble magnetic or metal oxide nanoparticles coated with ligands, preparation method and usage thereof: This invention provides water-soluble magnetic or water-soluble metal oxide nanoparticles, which are coated with phase transfer ligands having an adhesive region, an adhesive region-crosslinking region, or an adhesive region-reactive region, and also provides a method of preparing water-soluble magnetic or metal oxide nanoparticles, the method including (1) synthesizing water-insoluble magnetic... Agent: Holme Roberts & Owen LLP
20090258078 - Antioxidant polymer nanocarriers for use in preventing oxidative injury: The present invention is a method for encapsulating active protein in a polymeric nanocarrier. The instant method employs homogenization at subzero temperatures so that enzyme activity is retained. Enzymes which can be encapsulated by the present method include, for example, antioxidant enzymes and xenobiotic detoxifying enzymes. Encapsulation of an enzyme... Agent: Howson & Howson LLP
20090258077 - Composition and method for treating or preventing white spot syndrome virus: The present invention relates to a composition and method for treating or preventing white spot syndrome virus of arthropod. The present invention is based on using Artemisia japonica extract, and preferably, a mixture of Artemisia japonica extract and Saururus chinensis extract as effective agent. More preferably, the present invention provides... Agent: Jones Day
20090258079 - Biocompatible block copolymer, use thereof and manufacturing method thereof: A biocompatible block copolymer having a hydrophobic segment composed of amino acid and hydroxycarboxylic acid and a hydrophilic segment composed of polyalkylene oxide, wherein the terminal not bonded to the hydrophilic segment of the hydrophobic segment is composed of an amino acid unit.... Agent: Wenderoth, Lind & Ponack, L.L.P.
20090258080 - Emu oil and fruit composition: A composition is provided comprising emu oil and processed whole fruit. The composition is in a form for either topical application to human skin or for internal ingestion.... Agent: Mcgarry Bair PC
20090258081 - New plant derived seed extract rich in essentially fatty acids derived from salvia hispanica l. seed: composition of matter, manufacturing process and use: A Salvia hispanica L. derived seed oil extract composition of matter containing from 60-88% PUFAs in a ratio of from 3.1:1-3.3:1 of ALA to LA, 4-100% of C-18 mono-unsaturated fatty acid, 1-5% of C-18 saturated fatty acid and 4-8% of C-16 saturated fatty acid in a mixed triglyceride form stable... Agent: Allen, Dyer, Doppelt, Milbrath & Gilchrist P.A.
20090258082 - Dried amnion and method for drying teatment of amnion: The present invention provides a dried amnion which is dried with maintaining tissues of a raw amnion and can be easily stored for a prolonged period of time. An amnion which is dried with maintaining cells and tissues of a raw amnion can be produced by repeating a pressure-reducing operation... Agent: Birch Stewart Kolasch & Birch
20090258085 - Emulsions and methods of their production: An emulsion including Dead Sea water is provided, as well as methods for making and using such an emulsion. The emulsion can also include a structured surfactant.... Agent: The Nath Law Group
20090258083 - Method of producing and applications of composition of hypochlorous acid: A method for preparing a stabilized antimicrobial hypochlorous acid solution by diluting an aged stock solution to provide a hypochlorous acid solution at a concentration of about 50 to about 7000 ppm at a pH range of about 2.8 to about 4.0. The antimicrobial hypochlorous acid solution maintains at least... Agent: Husch Blackwell Sanders, LLP Husch Blackwell Sanders LLP Welsh & Katz
20090258084 - Mono and combination therapy with a m1/m4 muscarinic agonist (sabcomeline) for treatment of cognitive disorders in schizophrenia: The invention relates to the use of a functional muscarinic M1/M4 receptor agonist such as the functional muscarinic M1/M4 receptor agonist or a pharmaceutically acceptable salt thereof, in particular sabcomeline or a pharmaceutically acceptable salt thereof in for the treatment of cognitive impairment in schizophrenia and to combination therapies for... Agent: Nixon & Vanderhye, PC
20090258086 - Biofilm extracellular polysaccharide solvating system: The invention provides a solvating system for the removal of biofilms which solvates the extracellular polysaccharide matrix holding it to a surface. The aqueous solvating system comprises water, a metal ion sequestering agent, and a solvating agent for an extracellular polysaccharide matrix, which is gentle enough to be used directly... Agent: Iplm Group, P.A.
20090258087 - Method to increase and accelerated rehabilitate the capacity for work: The method to increase and accelerated rehabilitate the capacity for work is characterized in that the person is exposed to gaseous products having the property to improve physical and psychological human capabilities during a period of preparing for extreme strains and/or after extreme strains; the exposure to gaseous products is... Agent: The Nath Law Group
20090258088 - Use of materials and external stimuli for synovectomy: This invention has as one of its aspects a method to provide a safe an effective treatment for synovectomy. The method involves the administration a material to the affected joint, allowing the material to localize in the synovial membrane, and then applying an external stimulus that interacts with the material... Agent: Karen L. Kimble Technology Law, PLLC
20090258089 - Chemo- and radiation-sensitization of cancer by antisense trpm-2 oligodeoxynucleotides: Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal... Agent: Larson & Anderson, LLC
20090258090 - Colon cleansing solution: The field of colonic diagnostic and surgical procedures is hampered by the lack of optimal means available to cleanse the colon. A compromise between convenient, distasteful, solid or low volume, hyperosmotic solutions which cause considerable fluid and electrolyte imbalances in patients and large volume, difficult to consume, iso-osmotic solutions has... Agent: Wilmerhale/boston
20090258091 - Compositions and methods for treating neurodegenerative diseases: The present invention relates to compositions and methods for treating neurodegenerative diseases. In some embodiments, the present invention provides compositions for treating and preventing presbycusis.... Agent: Casimir Jones, S.c.
20090258092 - Improved tissue maintenance: The invention provides a method of reducing damage to a tissue, organ or cell from surgical procedures comprising administering a composition comprising a potassium channel opener/agonist and/or an adenosine receptor agonist (eg. adenosine) together with a local anaesthetic (eg. lignocaine) when perfusing the organ.... Agent: Venable LLP
20090258093 - Use of a brassocattleya marcella koss orchid extract as an active agent to prevent or delay the appearance of signs of cutaneous aging: The present invention describes the use of an extract from the Brassocattleya marcella Koss orchid, in a cosmetic composition or for the preparation of a cosmetic composition, as a hydrating and/or anti-aging agent designed to prevent or delay the appearance of signs of intrinsic or extrinsic aging of the skin,... Agent: Foley And Lardner LLP Suite 500
20090258094 - Xanthohumol-enriched hop extract: A method for preparing a xanthohumol-rich hop composition. The method includes providing a solution that contains xanthohumol-containing hop substances and effecting precipitation of non-xanthohumol hop substances by adjusting both the salt concentration and pH value of the solution. The xanthohumol-rich hop composition prepared by this method can be used for... Agent: Edwards Angell Palmer & Dodge LLP
20090258095 - Use of a ginkgo biloba extract for the treatment of mitochondrial disease of genetic origin: The invention relates to the use of Ginkgo biloba for the treatment of mitochondrial diseases of genetic origin and more particularly mitochondrial encephalomyophathies.... Agent: Hunton & Williams LLP Intellectual Property Department
20090258096 - Anticancer methods employing extracts of gleditsia sinensis lam: Selective apoptotic extracts of Gleditsia sinensis Lam are provided. Also provided are methods of using said extracts to induce apoptosis in specific cells, especially in a human. Provided as well are uses of the extracts of Gleditsia sinensis Lam for the preparation of a medicament for the selective induction of... Agent: Wilson, Sonsini, Goodrich & Rosati
20090258097 - Extracts and compounds from \"agapanthus africanus\" and their use as biological plant protecting agents: The invention relates to plant extracts, especially based on species of the genus Agapanthus and combinations thereof with other extracts deriving from other plants. The invention further relates to the isolation, purification and identification of compounds in these extracts. The plant extracts and the isolated substances show significant antimicrobial activity,... Agent: Arent Fox LLP
20090258098 - Penetrating carrier, antifungal composition using the same and method for treatment of dermatophyte infections: An antifungal composition and penetrating carrier system for topical treatment of dermatophytic infection and secondary bacterial infections. The antifungal composition includes various fungistatic and fungicidal essential oil components, or combinations thereof. The penetrating carrier system may include various ingredients, including a penetration enhancer, such as isopropyl myristate.... Agent: David B. Tingey10/08/2009 > patent applications in patent subcategories. categorized by USPTO classification
20090252673 - Methods of making and using rubidium-81-containing compositions: The present invention relates to preparation of imaging compositions containing Rubidium-81. In addition, the present invention relates to uses of Rubidium-81-containing compositions in diagnostic imaging such as, for example, myocardial imaging.... Agent: Mallinckrodt Inc.
20090252672 - Nasal delivery of therapeutic agents using tight junction agonists: The invention relates to a therapeutic composition comprising a therapeutically effective amount of one or more therapeutic agents and a nasal mucosa absorption-enhancing amount of one or more tight junction agonists. The invention further relates to a method of treating a subject comprising intranasally administering the composition of the invention... Agent: Cooley Godward Kronish LLP Attn: Patent Group
20090252676 - N-alkoxyamide conjugates as imaging agents: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging... Agent: Wolf Greenfield & Sacks, P.C.
20090252677 - Probes for in vivo targeting of active cysteine proteases: Activity-based probes, which are specific for certain active cysteine proteases (caspase, cathepsin and legumain) and carry radioactive labels, are disclosed. The present probes comprise an acyloxymethyketone (AOMK) “warhead” that binds only to active enzyme. The probes further comprise peptide-like structure that targets the probe to a specific cysteine protease or... Agent: Peters Verny , L.L.P.
20090252675 - Radionuclide therapy for urinary bladder cancer: The compounds used in this method for the treatment of bladder cancer comprise a radioisotope particle emitter, such as alpha- or beta-emitters or low energy gamma-emitters, associated with a chelating agent (for metallic radioisotopes) or other compound (by covalent bond for iodine or other non-metals) selected such that these permit... Agent: Technology Law, PLLC
20090252674 - Tripodal ligands with the coordinating motifs k2 -bh2 or k3 -bh3 relevant for biomedical applications of organometallic complexes: The present invention relates to a compound for use as a chelator in the radioactive labeling of biomolecules with metal tricarbonyl complexes, which compound has the general Formula (I) wherein M is a monovalent cation, such as Li, Na, K, Tl, Rb, Cs or an alkyl ammonium; R1 is H,... Agent: Mallinckrodt Inc.
20090252678 - Cox-2-targeted imaging agents: The presently disclosed subject matter provides a method for synthesizing a radiological imaging agent by reacting a COX-2-selective ligand with a compound comprising a detectable group, wherein the COX-2-selective ligand is a derivative of a non-steroidal anti-inflammatory drug (NSAID) comprising an ester moiety or a secondary amide moiety. Also provided... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.
20090252679 - Novel compound having affinity for amyloid: wherein A1, A2, A3 and A4 independently represents a carbon or nitrogen; R1 is a halogen substituent; R2 is a halogen substituent; and m is an integer of 0 to 2, provided that at least one of R1 and R2 is a radioactive halogen substituent, at least one of A1,... Agent: Fitch, Even, Tabin & Flannery
20090252680 - Novel compound with affinity for amyloid: wherein each of A1, A2, A3 and A4 independently represents a carbon or nitrogen; R1 is a group selected from the group consisting of hydrogen, hydroxyl group, carboxyl group, sulfuric acid group, amino group, nitro group, cyano group, non-radioactive halogen substituents, alkyl substituents with 1-4 carbon atoms and alkoxy substituents... Agent: Fitch, Even, Tabin & Flannery
20090252682 - In-vivo optical imaging method including analysis of dynamic images: In-vivo optical molecular imaging methods for producing an image of an animal are described. A time series of image data sets of an optical contrast substance in the animal is acquired using an optical detector Each image data set is obtained at a selected time and has the same plurality... Agent: Occhiuti Rohlicek & Tsao, LLP
20090252681 - Nanobodies and polypeptides against egfr and igf-ir: The invention relates to polypeptides and Nanobodies against Epidermal Growth Factor Receptor (EGFR) and/or Insulin Growth Factor-I Receptor (IGF-IR). The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or... Agent: Wolf Greenfield & Sacks, P.C.
20090252683 - Composition comprising cross-species-sepecific antibodies and uses thereof: The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of... Agent: Foley And Lardner LLP Suite 500
20090252684 - Determination of tissue-specific profile of amino acid requirements form the relationship between the amounts of trnas for individual amino acids and the protein-bound amino acid profile of the tissue: Systems and methods by which optimal profiles of amino acids for specific tissues can be determined. The results of these systems and methods can then be sued to generate medical nutrition products targeting specific tissues either to enhance growth of specific tissues by providing complementary amino acids in a nutritional... Agent: Lewis, Rice & Fingersh, Lc Attn: BoxIPDept.
20090252685 - High penetration prodrug compositions of prostaglandins and related compounds: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of prostaglandins or prostaglandin analogs which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent prostaglandins or prostaglandin analogs after crossing the biological barrier and... Agent: Perkins Coie LLP
20090252686 - Ex vivo hyperpolarization of imaging agents: The present invention generally relates to methods for accelerating the ex vivo induction of nuclear hyperpolarization in imaging agents.... Agent: Choate, Hall & Stewart/harvard University
20090252688 - Magnetic resonance contrast medium containing an iron-binding protein: An inventive principle of at least one embodiment is based on linking an iron-binding functionality in the form of a bacterial iron-binding protein to a binding element which specifically recognizes a biological structure, in order to increase a local detectable increase in the concentration of the contrast medium. In at... Agent: Harness, Dickey & Pierce, P.L.C
20090252687 - Asymmetric fluoro-substituted polymethine dyes: The present invention relates to improved conjugates of biological molecules with an improved class of water-soluble, green to near infra-red (NIR) cyanine labelling dyes. The dyes are asymmetric fluoro-substituted polymethines, and exhibit a high degree of photostability and reduced dye-dye quenching, as well as a high fluorescence quantum yield. The... Agent: Ge Healthcare, Inc.
20090252689 - Hair styling composition: e
20090252690 - Flavoured mouth wash composition: The present invention provides a flavoured product comprising four or more flavour materials having antimicrobial properties and selected from the group comprising nonanol, decanol, nonanal, decanal, amyl propionate, anethole synthetic, anisic aldehyde, basil oil, benzyl benzoate, benzyl butyrate, benzyl formate, chamomile oil, cinnamic aldehyde, cis-3-hexenol, clove bud oil, damascone, ethyl... Agent: Morgan Lewis & Bockius LLP
20090252692 - Esterified fatty acid composition: The invention is directed to compositions comprising lecithin, olive oil, esterified fatty acids and mixed tocophenols for use in the treatment and prevention of various types of arthritis and other inflammatory joint conditions, periodontal diseases and psoriasis, which avoid many of the side effects associated with known treatments. The compositions... Agent: Techlaw LLP
20090252691 - Foam manipulation compositions containing fine particles: A foam manipulation stabilizing composition for use in consumer products includes a plurality of surface-modified particles in combination with at least one surfactant. The particles have an average particle size greater than 100 nm up to about 50 μm and a hydrophobicity measured by a contact angle between about 20°... Agent: The Procter & Gamble Company Global Legal Department - Ip
20090252693 - Process for preparing dispersions of tio2 in the form of nanoparticles, and dispersions obtainable with this process and functionalization of surfaces by application of tio2 dispersions: A process for preparing nanoparticulate dispersions of TiO2 in crystalline anatase form and the dispersions obtained with the process, useful for preparing photocatalytic coatings on surface and the photocatalytic decontamination of gas and liquids.... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP
20090252694 - Novel chalcone derivatives, pharmaceutically acceptable salt, method for preparation and uses thereof: Disclosed relates to a novel chalcone derivative, pharmaceutically acceptable salt thereof, a method for preparing the same and uses thereof, the chalcone derivative being readily obtained through the steps of: reacting aminoacetophenone with sulfonylchloride under the presence of an appropriate salt; and reacting the compound prepared in the above step... Agent: Lucas & Mercanti, LLP
20090252695 - Special effects with mixtures of interference pigments: A method of producing mixtures of interference pigments having special effects comprises mixing at least one large particle size interference pigment with at least one normal size interference pigment of predetermined colors and in proportions desired to obtain a unique effect.... Agent: Millen, White, Zelano & Branigan, P.C.
20090252696 - Hair straightening composition comprising urea: An aqueous based hair straightening composition having a pH from 12 to 14 comprising i) an hydroxide ion generator; and ii) from 0.5 wt % to 20 wt % of the total composition of urea in which the weight ratio of urea to hydroxide generator is greater than 1:1.... Agent: Unilever Patent Group
20090252697 - Method for permanently reshaping keratin fibers with an acid pre-treating composition: A method for permanently reshaping keratin fibers, such as hair, comprising applying onto the keratin fibers a pre-treating composition comprising, in a cosmetically acceptable medium, at least one entity chosen from non reducing inorganic acids, non reducing organic acids, and salts thereof, wherein the pH value of said pre-treating composition... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20090252698 - Emulsion compositions for eyelashes: The invention relates to emulsion compositions for application to eyelashes containing at least one surfactant comprising silicone, hydrocarbon and glycerol group(s), as well as to methods of applying such compositions to eyelashes and kits containing such compositions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.
20090252699 - Medical devices with an antimicrobial polyurethane coating: The present invention relates to a medical device comprising a coating which is obtainable starting from a solution comprising a nonionic polyurethaneurea and silver.... Agent: Connolly Bove Lodge & Hutz, LLP
20090252700 - Hydroxyphenyl cross-linked macromolecular network and applications thereof: A synthetic nucleus pulposus is provided that is useful in treatment of degenerative disc disease, augmentation of a degenerate disc, and alleviation of back pain. In an embodiment the synthetic nucleus pulposus comprises hyaluronan macromolecules that have been cross-linked via dihydroxyphenyl linkages. The synthetic nucleus pulposus restores or improves the... Agent: Pearne & Gordon LLP
20090252701 - Biostatic polymer: Methods and compositions effective for at least a week for prevention of microbial colony growth on a surface, for example an inanimate surface, where the surface is covered with a dry or substantially dry film formed from a composition comprising a polyvinyl alcohol and a quaternary ammonium compound. The film... Agent: Wolf Greenfield & Sacks, P.C.
20090252702 - Polymer-based anti-cancer agents: The present invention relates to the use of amphiphilic block copolymers for treating and preventing cancer, and in particular by reducing the proliferation rate of cancer cells. Preferred block copolymers comprises a central hydrophobic chain, preferably a polypropylene oxide chain, two which at least two hydrophilic side chains, preferably polyethylene... Agent: Young & Thompson
20090252705 - Il-6/il-6r fusion protein: The present invention relates to a fusion protein comprising a functional IL-6 molecule and a functional DS-sIL-6R molecule. The present invention also relates to a nucleic acid encoding the fusion protein, methods of producing the fusion protein, and the use of the fusion protein in the treatment of infectious diseases... Agent: Banner & Witcoff, Ltd.
20090252704 - Therapies for cognition and learning enhancement: The invention relates to a combination comprising an amount of an NO donor, such as ISDN, and/or an amount of another pharmaceutical agent that enhances neurotransmission or which acts as neuroprotectants such as memantine, clomethiazole and tacrine. These compositions can be used in producing cognition and learning enhancement, whereby the... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000
20090252703 - Use of alcohol co-solvents to improve pegylation reaction yields: Disclosed is a method of producing a composition of matter. The method involves obtaining a pharmacologically active peptide; and conjugating the peptide to a pharmaceutically acceptable polyethylene glycol (PEG) by reacting the peptide with a PEG-aldehyde compound at a free amine moiety on the peptide in a buffer solution comprising... Agent: Amgen Inc.
20090252706 - Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer: The invention relates to compounds of formula (I) wherein Ra is —C(O)ORI, in which R1 is 1-7C-alkyl. 3-7C-cycloakyl, 1-7C-alkyl substituted by Raa, or 2-7C-alkyl substituted by Rab and Rac on different carbon atoms, Rb is -T-Q, in which T is 1-6C-alkylene or 3-7C-cycloalkylene, and Q is substituted by Rba and... Agent: Millen, White, Zelano & Branigan, P.C.
20090252707 - Novel expression vectors and uses thereof: A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a... Agent: Buchanan, Ingersoll & Rooney PC
20090252714 - Autoantigenes for improved diagnosis, prognosis and treatment of inflammatory neurological diseases: According to the invention, autoantibodies, the appearance of which is characteristic of neurological autoimmune diseases, especially multiple sclerosis, are detected and the respective autoantigens identified. It can further be shown that many of these autoantigens are expressed specifically in the brain. The identification of the autoantigens and autoantibodies is useful... Agent: Mcandrews Held & Malloy, Ltd
20090252713 - Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy: A circular DNA molecule, useful for gene therapy, comprising at least one nucleic acid sequence of interest, characterised in that the region allowing the replication thereof has an origin of replication with a functionality in a host cell that requires the presence of at least one specific protein foreign to... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20090252715 - Immortalization of mammalian cells: Genomic instability in T antigen expressing cells can be overcome by modifying the gene expressing T antigen so that it lacks Bub1 binding. Stable cell lines can be produced by incorporation of the modified T antigen gene, preferably together with the catalytic sub-unit of the telomerase construct.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20090252708 - Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof: Biotherapeutic compositions of a non-pathogenic bacterial strain such as M-17 and its substrains and an anaerobic bacterial antibiotic such as metronidazole, are disclosed. Further disclosed are uses of M-17 or its substrains and an anaerobic bacterial antibiotic for treating disorders caused by anaerobic bacteria, whereby such disorders include, for example,... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.
20090252709 - Novel bacterium belonging to the genus bifidobacterium and utilization of the same: It is intended to provide Bifidobacterium bifidum which has an effect of killing Helicobacter pylori and shows high survivability even in the case of being stored in a fermented milk food or drink under aerobic condition. The Bifidobacterium bifidum has the following characteristics: (1) having an effect of killing Helicobacter... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.
20090252712 - Chimeric c3-like rho antagonist bone therapeutic: Methods of treating bone disorders in a subject in need thereof by administering to said subject a therapeutically effective amount of a Rho antagonist are disclosed.... Agent: Wilmerhale/boston
20090252711 - Stem cells and methods of making and using stem cells: The invention provides a method of making a pluripotent stem cell from a cell that is not pluripotent, such as from a differentiated stem cell or a lineage-restricted stem cell. The methods comprise culturing the starting cell in the presence of one or more epigenetic altering agents, such as a... Agent: Casimir Jones, S.c.
20090252710 - Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of... Agent: Jones Day
20090252716 - Methods for identifying nuclear receptor/ligand combinations for targeting brain tumor stem cells and for their use: An in vitro method is provided for identifying nuclear receptors abnormally expressed by brain tumor stem cells and a corresponding ligand which, if administered to brain tumor stem cells (BTSC's), is capable of inhibiting cell proliferation. Once the nuclear receptor/ligand combination has been identified, it can be utilized in vitro... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP
20090252717 - Compositions and methods for treating polyglutamine-expansion neurodegenerative diseases: The invention relates to methods for stimulating fast axonal transport in polyglutamine expansion diseases and treating polyglutamine expansion diseases by inhibiting SAPK-dependent phosphorylation of kinesin. The present invention also provides methods for identifying agents which inhibit the phosphorylation of the kinesin, as well as methods for monitoring treatment of a... Agent: Licata & Tyrrell P.C.
20090252718 - Phospholipase(s) and use(s) thereof: The invention relates to phospholipase(s), isoforms, derivatives, mutants and/or fragments thereof, for the preparation of a medicament for the treatment and/or prevention of ischemia. Preferred is the use of secretory phospholipase, particularly phospholipase A2, and even more particularly phospholipase A2 derived from the snake venom of Naja sputatrix... Agent: Dickstein Shapiro LLP
20090252719 - Use of fructanases in feed of hoofed animals, preferably to prevent diseases: Laminitis is defined as an inflammation of the sensitive laminae of the hoof, especially in horses. It has been surprisingly found that fructanases such as 2,1-β-D-fructan hydrolase are highly effective as therapeutic and prophylactic agents against laminitis in horses. The fructanases may be used as enzyme compositions in horse feed,... Agent: Nixon & Vanderhye, PC
20090252720 - Prolonged fix analogues and derivatives: The invention is related to FIX analogues which have an increased circulation time in the blood stream before activation compared to that that of native FIX (and a week after injection to a patient retains at least about 5% of the FIX activity compared to the initial activity peak value... Agent: Novo Nordisk, Inc. Intellectual Property Department
20090252722 - Botulinum neurotoxin a protein receptor and uses thereof: The invention relates to a polypeptide comprising an amino acid sequence, at least 70 percent of which are identical to the amino acid sequence of the synaptic vesicle glycoprotein of homo sapiens. Said polypeptide binds the HC fragment of botulinum neurotoxin A provided that the polypeptide is not the synaptic... Agent: Hamilton, Brook, Smith & Reynolds, P.C.
20090252721 - Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer: The invention relates to agents and methods for the diagnosis, prognosis and treatment of cancer. Specifically, the invention relates to the use of nucleic and amino acid sequences encoding transmembrane superfamily member 6 (TM4SF6), synaptophysin like protein (SYPL), stomatin like 2 (STOML2), Ras related GTP binding protein RAGA), nucleotide sensitive... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000
20090252724 - Antibodies against amyloid beta 4 with glycosylated in the variable region: The present invention relates to a purified antibody molecule preparation being characterized in that at least one antigen binding site comprises a glycosylated asparagine (Asn) in the variable region of the heavy chain (VH). More specifically, a pharmaceutical and a diagnostic composition comprising said antibody molecule and antibody mixtures are... Agent: Stephen M. Haracz Bryan Cave
20090252726 - Antibodies for inhibiting blood coagulation and methods of use thereof: The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:FVIIa complex, effectively preventing factor... Agent: Morrison & Foerster LLP
20090252727 - Glucagon receptor antagonists: The present invention relates to glucagon receptor polypeptide antagonists which inhibit the binding of the hormone glucagon to its receptor. More particularly, the present invention relates to high affinity glucagon receptor antibodies or Fab fragments thereof that inhibit binding of glucagon to its receptor and their use in the treatment... Agent: Eli Lilly & Company
20090252723 - Remedy for endometriosis: The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.... Agent: Sughrue-265550
20090252725 - Use of cd23 antibodies to treat malignancies in patients with poor prognosis: The invention relates to methods of treating B-cell chronic lymphocytic leukemia, and other CD23+ malignancies, in patients with poor prognostic markers. The method comprises administration of an CD23 antibody, including for example, lumiliximab to a mammal that over expresses a poor prognostic marker. The method can also comprise administration of... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.
20090252730 - Methods of treating skin disorders using an il-31ra antagonist: The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.... Agent: Zymogenetics, Inc. Intellectual Property Department
20090252728 - Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.... Agent: Agensys C/o Morrison & Foerster LLP
20090252729 - Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto: The present invention features inter alia polypeptides comprising an Fc region comprising genetically-fused Fc moieties. In addition, the instant invention provides, e.g., methods for treating or preventing a disease or disorder in subject by administering the binding polypeptides of the invention to said subject.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000
20090252731 - Multivalent carriers of bi-specific antibodies: Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targetable construct with two or more bi-specific antibodies. The... Agent: Immunomedics, Inc.
20090252734 - Antihuman alpha 9 integrin antibody and use of the same: The present invention relates to: an antibody (particularly a monoclonal antibody), a chimeric antibody, a humanized antibody and a human antibody, which specifically recognize human α9 integrin; a hybridoma cell which produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a... Agent: Ladas & Parry LLP
20090252733 - Generation and profiling of fully human gold-derived therapeutic antibodies specific for human cd38: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such... Agent: Foley And Lardner LLP Suite 500
20090252736 - Mammalian genes; related reagents: Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.... Agent: Schering-plough Biopharma Legal Department
20090252735 - Novel peptides for development of diagnostic and therapeutic agents and methods of using same: Novel immuno-interactive fragments of the αC portion of a mammalian inhibin α subunit, together with their variants and derivatives, produce antigen-binding molecules that are interactive with the αC portion, and which are chemically well defined and which can be produced in commercially significant quantities. The antigen-binding molecules of the invention... Agent: Panitch Schwarze Belisario & Nadel LLP
20090252737 - T cell regulatory genes and methods of use thereof: A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family... Agent: Ballard Spahr Andrews & Ingersoll, LLP
20090252732 - Variable region sequences of il-31 monoclonal antibodies and methods of use: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by... Agent: Zymogenetics, Inc. Intellectual Property Department
20090252739 - Cerebral infarction suppressant: An objective of the present invention is to provide a suppressant for cerebral infarction occurred after long-term ischemia associated with actual cerebral infarction, and has fewer side effects. The cerebral infarction suppressant of the present invention is characterized in comprising an anti-HMGB1 monoclonal antibody as an active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.
20090252738 - Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix: Compositions and methods useful in inhibiting proliferation of CA IX+preneoplastic or neoplastic cells in a mammal are provided. The compositions are antagonist anti-CA IX antibodies and other inhibitory agents that target carbonic anhydrase activity of CA IX on these cells. The antagonist anti-CA IX antibodies or antigen-binding fragments thereof are... Agent: Novartis Vaccines And Diagnostics Inc.
20090252740 - Method for predicting responsiveness to tnf alpha blocking agents: The invention provides an in vitro method for predicting whether a patient would be responsive to a treatment with a TNFα blocking agent, which method comprises determining the expression level of eight genes in a biological sample of said patient, wherein said genes are EPS15, HLA-DPB1, AKAP9, RASGRP3, MTCBP-1, PTNP12,... Agent: Occhiuti Rohlicek & Tsao, LLP
20090252741 - Human monoclonal anti-ctla4 antibodies in cancer treatment: Although results from preclinical studies in animal models have proven the concept for use of anti-CTLA-4 antibodies in cancer immunotherapy, two major obstacles have hindered their successful application for human cancer therapy. First, the lack of in vitro correlates of the anti-tumor effect of the antibodies makes it difficult to... Agent: Calfee Halter & Griswold, LLP
20090252743 - Anti-tnf antibodies, compositions, methods and uses: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS: 1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha... Agent: Philip S. Johnson Johnson & Johnson
20090252742 - Il3ralpha antibody conjugates and uses thereof: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and/or cancer stem cells)... Agent: Jones Day
20090252744 - Methods for treating bone cancer pain by administering a nerve growth factor antagonist antibody: The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) antibody that is capable of binding hNGF.... Agent: Pfizer Inc. Patent Department
20090252745 - Amino acids in the hcv core polypeptide domain 3 and correlation with steatosis: The presently disclosed subject matter provides methods and compositions for predicting a tendency of a subject infected with hepatitis C virus (HCV) to develop steatosis. In some embodiments, the disclosed methods include the steps of (a) isolating from the subject a biological sample comprising an HCV Core polypeptide or a... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.
20090252746 - Erythropoietin receptor binding antibodies: The present invention relates to antibodies and antibody fragments thereof that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies as well as pharmaceutical compositions containing said antibodies.... Agent: Paul D. Yasger Abbott Laboratories
20090252747 - Nucleic acids and corresponding proteins entitled 282p1g3 useful in treatment and detection of cancer: A novel gene 282P1G3 and its encoded protein, and variants thereof, are described wherein 282P1G3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 282P1G3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 282P1G3 gene or... Agent: Agensys C/o Morrison & Foerster LLP
20090252748 - Sp35 antibodies and uses thereof: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.
20090252750 - Antibodies and immunotoxins that target human glycoprotein nmb: The invention provides high affinity antibodies suitable for forming immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells.... Agent: Banner & Witcoff, Ltd.
20090252749 - Compositions and methods for producing a composition: The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.... Agent: Louis J. Wille Bristol-myers Squibb Company
20090252751 - Immune adjuvant comprising ubiquinone: This invention relates to an immunoadjuvant, which has an excellent antibody production enhancing function and is highly safe, and a vaccine composition comprising the immunoadjuvant. More specifically, the present invention relates to an immunoadjuvant comprising a ubiquinone represented by formula (I), and a vaccine composition comprising the ubiquinone represented by... Agent: Wenderoth, Lind & Ponack, L.L.P.
20090252753 - Immunomodulation for autoimmune type-2 diabetes: The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant.... Agent: Cohen & Grigsby, P.C.
20090252752 - Kdr peptides and vaccines comprising the same: The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:29, 30, 33, 34, 40, or 46; and peptides with cytotoxic T cell... Agent: Townsend And Townsend And Crew, LLP
20090252754 - Vaccines containing the hiv tat protein as an adjuvant for the enhancement of cytotoxic t-cell responses: Tat, when used in a vaccine, causes MHC-I to expose subdominant epitopes present within an antigen, thereby enabling an optimal immune response to be generated, within an individual, against the antigen and variants of the antigen, such as might be encountered with HIV or influenza viruses.... Agent: Foley & Lardner LLP
20090252755 - Cloned genome of infectious hepatitis c virus strain hc-tn and uses thereof: Embodiments described herein include nucleic acid sequences, which encode hepatitis C virus of strain HC-TN, genotype 1a, proteins and polypeptides and fragments thereof. Use of these compositions, and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV are also contemplated.... Agent: Knobbe, Martens, Olson & Bear, LLP
20090252756 - Protein-based streptococcus pneumoniae vaccines: Vaccine compositions and methods for protecting a mammalian subject against infection with S. pneumoniae are disclosed. The vaccines and methods comprise an effective amount of one or more Streptococcus pneumoniae cell wall and/or cell membrane proteins and/or immunogenically-active fragments, derivatives or modifications thereof, wherein said proteins are selected from a... Agent: Winston & Strawn LLP Patent Department
20090252757 - Methods and compositions for inhibiting hiv infection: This invention provides novel HIV-interacting host factors. The invention also provides methods of using the HIV-interacting host factors to screen for compounds that inhibit HIV infection. The methods comprise first screening test compounds for modulators of an HIV interacting host factor disclosed herein, and then further screening the identified modulating... Agent: Genomics Institute Of The Novartis Research Foundation
20090252758 - Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance: A mixture is formulated that is capable of improving a person's well being, lowering the risks of cardiovascular and/or Alzheimer's diseases and/or lowering blood sugar using natural and synthetic ingredients. A mixture of the present invention may be used as a food, a drink, a supplement or potentially a drug.... Agent: Haynes And Boone, LLPIPSection
20090252759 - Immunogenic composition: The present application relates to an immunogenic composition comprising at least 2 conjugates of N. meningitidis capsular saccharide and protein carrier, wherein said conjugates comprise at least 2 different N. meningitidis capsular saccharides selected from the group consisting of MenA, MenC, MenY and MenW, wherein at least one capsular saccharide... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220
20090252760 - Construction of recombinant adenovirus with genes that codify for sag1, sag2 and sag3: This invention refers to the construction of recombinant adenovirus with genes that codify for T. gondii SAG1, SAG2 and SAG3, through a homologue recombination technique between two vectors. A first vector that serves as transference vector of genes and a second vector that bears the adenoviral receptor genome of these... Agent: David H. Voorhees Merek, Blackmon & Voorhees
20090252761 - Papilloma virus vaccine: A method of providing papilloma virus like particles which may be used for diagnostic purposes or for incorporation in a vaccine for use in relation to infections caused by papilloma virus. The method includes an initial step of constructing one or more recombinant DNA molecules which each encode papilloma virus... Agent: Foley And Lardner LLP Suite 500
20090252762 - novel proteosome-liposaccharide vaccine adjuvant: An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type... Agent: Seed Intellectual Property Law Group PLLC
20090252763 - Biological adjuvants: A method of enhancing uptake of DNA by a host cell line comprises introducing the DNA into the host cell and contacting the host cell with non-infectious viral particles. The non-infectious particles may be L-particle or PREPS (pre-viral DNA replication envelope particles), for example, those derived from alpha herpesvirus.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.
20090252764 - Suture line administration technique using botulinum toxin: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon... Agent: Allergan, Inc.
20090252765 - Bacille calmette-guerin (bcg)-based anti-atheroma vaccine and methods of use thereof: The invention relates to a recombinant Mycobacterium bovis which expresses at least one Chlamydophila pneumoniae antigen.... Agent: Alston & Bird LLP
20090252766 - Attenuated gram negative bacteria: Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an... Agent: Frommer Lawrence & Haug
20090252770 - Non-digestible sugar-coated products and process: A method and composition are provided for coating a component to achieve colon-targeted delivery. A component is coated with a fructose-based non-digestible carbohydrate such as a inulin, fructo-oligosaccharide or neosugar. The coated component is orally administered to a monogastric animal. The non-digestible coating causes the composition to pass through the... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property
20090252769 - Preventive and therapeutic vaccine for storke and neurological disorders: A method for producing therapeutic vaccine which consist of NMDA-NR1 subunit expressed in insect cells to produce recombinant protein and was encapsulated in poly(D-L-lactide-co-glycolic-acid) (PGLA) microparticles by solvent exchange and used for oral immunization. Thus the experimental model for stroke has been developed for the study of powerful N-methyl-d-aspartic acid... Agent: Jeeri R. Reddy
20090252768 - Use of stilbene derivatives for treatment and prevention of aquatic mold infections: The invention relates to methods of treatment and prevention of aquatic mold infections in aquatic organisms and methods of disinfecting equipment used in raising aquatic organisms. The methods comprise use of one or more stilbene derivatives, including 4,4′-bis-(1,3,5-triazinylamino)stilbene-2,2′-disulfonic acid derivatives.... Agent: Fennemore Craig
20090252767 - Water dispersible enteric coating formulation of nutraceutical and pharmaceutical dosage forms: The present invention relates to formulations for use as enteric coatings. More particularly, the present invention relates to a formulation comprising a dry blend of food grade ingredients that can be readily dispersed in water. This dispersion exhibits low viscosity and can easily be coated onto solid dosage forms through... Agent: Hercules Incorporated Hercules Plaza
20090252773 - Emulsion composition: An emulsion composition of the present invention includes (A) a salt of a higher fatty acid ester of ascorbic acid-2-phosphoric acid ester, (B) a polyglycerin fatty acid monoester including polyglycerin having a mean polymerization degree of 8 to 12 and an unsaturated fatty acid residual group of 14 to 22... Agent: Sughrue Mion, PLLC
20090252771 - Method for obtaining o/w cosmetic emulsions with high water resistance: This invention relates to a method for obtaining cationic O/W emulsions designed for skin care, which present high water resistance associated with excellent “skin feeling” characteristics.... Agent: Birch Stewart Kolasch & Birch
20090252775 - Virucidal disinfectant: A virucidal disinfectant having broad-range activity includes an acidic phosphorus compound and/or salt thereof, an alcohol, and one or more polyalkylene glycols. The disinfectant, which may also kill bacteria and/or fungi, may be used for the hygienic disinfection of animate and inanimate surfaces. The invention also provides a disinfection method... Agent: Ratnerprestia
20090252776 - Animal deterrent for protecting plants: The invention provides materials, compositions, methods, and kits for deterring or repelling animals from eating plant materials. The invention relates to the use of particulate matter to deter animals from eating plant materials that are susceptible to grazing by animals. In exemplary embodiments, an adhesive is applied to target plant... Agent: Latimer, Mayberry & MatthewsIPLaw, LLP
20090252779 - Azaindazole compounds and methods of use: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.... Agent: Townsend And Townsend And Crew, LLP
20090252780 - Coatings for implantable medical devices: Coatings for implantable medical devices comprising non-fouling moieties or polymers chemically bonded to the surface of the device via chelating structures, and methods of fabricating the coatings are disclosed.... Agent: Squire, Sanders & Dempsey LLP
20090252777 - Method for formulating a controlled-release pharmaceutical formulation: Methods for making formulations of drugs and crystalline side chain polymers which formulations provide controlled and/or sustained release drug formulations.... Agent: Bell & Associates
20090252778 - Methods and devices for reducing tissue damage after ischemic injury: Methods and devices are provided for the delivery of therapeutic agents which reduce myocardial tissue damage due to ischemia and anti-restenotic agents which inhibit restenosis following a cardiac procedure such as stent implantation. The anti-ischemia agents are delivered to the myocardial tissue over an administration period sufficient to achieve reduction... Agent: Philip S. Johnson Johnson & Johnson
20090252781 - Hydrogel polymeric compositions and methods: Some aspects of this disclosure relate to a method of treating an opthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreal site for controlled release of a therapeutic agent.... Agent: Dardi & Asscociates, PLLC US Bank Plaza, Suite 2000
20090252782 - Transdermal preparations containing hydrophoic non-steroidal anti-inflammatory drugs: Disclosed is a transdermal preparation containing a hydrophobic drug. As a method of continuing the high drug permeation, it is used an unique hydrophilic polymer system in which the drug can be contained in a high concentration under no water environment, a solubility of the hydrophobic drug is decreased as... Agent: Merchant & Gould PC
20090252784 - Compositions comprising inhibitors of rna binding proteins and methods of producing and using same: Compositions for inhibiting RNA binding proteins, as well as methods of producing and using the same, are disclosed herein.... Agent: Dunlap Codding, P.C.
20090252785 - Endoplasmic reticulum targeting liposomes: Provided are compositions that include lipid particles, such as liposomes, that can fuse with the ER membrane of a cell. The lipid particles can also deliver a cargo, such as a therapeutic or an imaging agent, encapsulated inside the particles inside the ER lumen of the cell. The compositions can... Agent: Foley And Lardner LLP Suite 500
20090252783 - Means for inhibiting the expression of cd31: The present invention is related to a nucleic acid molecule comprising a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20090252786 - Use of a biologically active blood serum for the treatment of a disorder characterized in a reduced function of a gaba receptor: The present invention relates to a method of preventing or treating in a subject a disorder characterized in a reduced GABA receptor function by administering to the subject a therapeutically effective amount of a pharmacologically active blood serum product obtainable by a method comprising electrostimulation of a non-human animal, withdrawal... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20090252787 - Granular pharmaceutical compositions: Pharmaceutical compositions comprising a plurality of formulated particles containing at least one active ingredient and at least one pharmaceutically acceptable excipient, granulated with a granulating composition containing at least one pharmaceutical excipient.... Agent: Dr. Reddy''s Laboratories, Inc.
20090252788 - Balsalazide formulations and manufacture and use thereof: The invention relates to formulations and dosage schedules of balsalazide. The invention further relates to methods of producing pharmaceutical formulations of balsalazide.... Agent: Edwards Angell Palmer & Dodge LLP
20090252789 - One step spray-drying process: Capsules encapsulating an active or functional ingredient are obtainable by a process in which a feed that includes this ingredient is dispersed in the form of drops in a spraying tower and exposed to a temperature in the range of −20° C. to 500° C. In the tower, a cloud... Agent: Winston & Strawn LLP Patent Department
20090252791 - Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug: Dosage forms for administering a triptan and a nonsteroidal anti-inflammatory drug are disclosed, including multilayered tablets and mini-tablets. These multilayered tablets can be in a side-by-side arrangement, can be inlayed, or one layer can completely surround another. These can be administered in a capsule or directly. Other formulations are also... Agent: Dr. Reddy''s Laboratories, Inc.
20090252790 - Tablet formulation: The present invention relates to a pharmaceutical fixed dose combination tablet comprising repaglinide and metformin. The present invention also provides a method of producing said tablet.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation
20090252792 - method to reduce the symptoms of heartburn and gastro-oesophageal reflux disease (gerd) by specific polysaccharides: The invention is directed to the use of a specific group of polysaccharides for reducing the symptoms or heartburn and gastroesophageal reflux isease. In addition, a pharmaceutical preparation is provided comprising a specific group of polysaccharides having a high hydration rate, a high viscosity, and a high stability at low... Agent: Morrison & Foerster LLP
20090252793 - Pharmaceutical compositions: Oral dosage forms comprising oxcarbazepine which when administered to a patient display no food effect.... Agent: Novartis Corporate Intellectual Property
20090252794 - Tablet: The present invention provides a novel tablet with improved tablet appearance and improved swallowability. The tablet contains a pharmaceutically acceptable anion exchange resin represented by colestimide as an active ingredient, and has a visibility-resolved tablet edge.... Agent: Wenderoth, Lind & Ponack, L.L.P.
20090252795 - Bioceramic scaffolds for tissue engineering: This invention relates to bioinert microporous bioceramic scaffolding, matrices or spheres comprising a particulate microporous bioinert ceramic material, which is a primary structure, and in the form of scaffolds, matrices or spheres, having interconnected pores. Pores on the surface of the spheres, matrices or scaffolds are connected to pores inside... Agent: Stuart K. J. Smyth
20090252796 - Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance: A mixture (which may be utilized as a food or a drink or a supplement or a drug or a cosmetic or a hygienic product) that is formulated and is capable of improving a person's well being, lowering the risks of cardiovascular and/or Alzheimer's diseases and/or lowering blood sugar using... Agent: Haynes And Boone, LLPIPSection
20090252797 - Topical application of ivermectin for the treatment of dermatological conditions/afflictions: Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective... Agent: Buchanan, Ingersoll & Rooney PC
20090252799 - Materials and methods for wound treatment: The subject invention pertains to materials and methods for stopping or decreasing the blood flow from an open wound or medical or surgical procedure. Compositions of the invention comprise a salt form of a cross-linked polyacrylic acid. In one embodiment, the composition comprises a sodium salt of a polyacrylic acid.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20090252798 - Matrix-gel graft without cells: A cell-free graft contains (i) a cohesive, scaffold-forming matrix with open porosity containing a biologically and pharmaceutically acceptable material, and (ii) a gel of a biologically and pharmaceutically acceptable material. The cell-free graft is produced by (v) contacting the matrix with the gel, and (vi) drying the matrix-gel complex formed... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.
20090252800 - Anisotropic nanocomposite hydrogel: Anisotropic nanocomposite hydrogel materials are created using a process in which a hydrogel-forming material is crosslinked in the presence of nanoscale cellulose and subsequently thermally cycled under an applied tensile strain. Such materials are capable of exhibiting high mechanical and viscoelastic anisotropy, increased stiffness when subjected to large strain, and... Agent: Dowell & Dowell P.C.
20090252802 - Compositions including relatively water insoluble/unwettable drugs and methods for using same: Compositions including therapeutic components and surfactant components which enhance the utility of the therapeutic components and methods of using such compositions are provided.... Agent: Allergan, Inc.
20090252803 - Glycyrrhetinic acid-mediated nanoparticles of hepatic targeted drug delivery system, process for preparing the same and use thereof: Disclosed are a hepatic targeted drug delivery system and a process for preparing the same. Also disclosed is a method for treating liver cancer.... Agent: James B. Conte Husch Blackwell Sanders LLP
20090252804 - Medical devices with an antibacterial polyurethaneurea coating: The present invention relates to a medical device which has at least one coating which is obtained starting from an aqueous dispersion, the aqueous dispersion comprising at least one nonionically stabilized polyurethaneurea and at least one silver-containing constituent.... Agent: Connolly Bove Lodge & Hutz, LLP
20090252801 - Process for the preparation of micronised sterile steroids: The present invention relates to a process for the preparation of micronised sterile steroids, comprising sterilisation of the steroids in crystalline form by means of irradiation with gamma or beta rays, and subsequent sterile micronisation.... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP
20090252805 - Film-coated and/or granulated calcium-containing compounds and use thereof in pharmaceutical compositions: Calcium-containing compounds have been at least partly film-coated and/or granulated with a water-soluble substance and a water-soluble polymeric substance and use of such coated compounds in pharmaceutical compositions. The at least partly film-coated and/or granulated calcium-containing compounds have proved suitable for the preparation of tablets having a very high load... Agent: Edwards Angell Palmer & Dodge LLP
20090252806 - Nanoparticulate tacrolimus formulations: The present invention is directed to nanoparticulate tacrolimus compositions. The composition comprising tacrolimus particles having an effective average particle size of less than about 2000 nm and at least one surface stabilizer.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner
20090252808 - Controlled release of biological entities: A process is provided for releasably encapsulating a biological entity. The process comprise combining a solution of a surfactant in a non-polar solvent with a precursor material and the biological entity to form an emulsion. The emulsion comprises a polar phase dispersed in a non-polar phase, wherein the polar phase... Agent: Foley And Lardner LLP Suite 500
20090252807 - Nanoparticulate and controlled release compositions comprising prostaglandin derivatives: The present invention is directed to compositions comprising a nanoparticulate prostaglandin derivative, preferably limaprost or a salt or derivative thereof, having improved bioavailability. The nanoparticulate prostaglandin derivative particles of the composition have an effective average particles size of less than about 2000 nm and are useful in the treatment of... Agent: Fox Rothschild, LLP Elan Pharma International Limited
20090252809 - Microcapsules from emulsion polymerization of tetraalkoxysilane: A process is disclosed for preparing microcapsules having a shell thickness of at least 18 nanometers by polymerizing a tetraalkoxysilane at the oil/water interface of an emulsion containing 0.1 to 0.3 weight percent of a cationic surfactant. The microcapsules are useful to prepare encapsulated sunscreens having sufficient robustness to prevent... Agent: Dow Corning Corporation Co1232
20090252810 - Aryl/alkyl succinic anhydride-hyaluronan derivatives: The present invention relates to the modification of hyaluronic acid (HA) with aryl/alkyl succinic anhydrides (ASA) to produce aryl/alkyl succinic anhydride HA derivatives, to the derivatives as such, and to their applications and uses, particularly in the cosmetic and biomedical industries. The ASA-HA derivatives are expected to have interesting properties... Agent: Novozymes North America, Inc.
20090252811 - Capped mesoporous silicates: The invention provides an article comprising, a mesoporous silicate matrix, such as a particle, having one or more pores; and one or more releasable caps obstructing one or more of the pores. The articles are useful as delivery vehicles for encapsulated agents such as therapeutic agents, polynucleotides, polypeptides and the... Agent: Schwegman, Lundberg & Woessner, P.A.
20090252812 - Use of fermented milk product for skin treatment: The use of a fermented milk product comprising non-hydrolysed whey proteins which is substantially free of casein proteins for the purpose of improving skin firmness, by structuring collagen without promoting collagen synthesis, when topically applied to skin is provided.... Agent: Norris, Mclaughlin & Marcus
20090252813 - Cercan: an energy supplement product for boosting the immune system: This invention concerns the process of creating an energy supplement product, good also as an anti-aging, aphrodisiac and as an alternative source to prevent or to remedy some diseases. The product is a composition of five ingredients: four marine animals (sea cucumber, sea urchin, sea sponge, and shark fin), and... Agent: Merek, Blackmon & Voorhees, LLC
20090252814 - Use of xenon for organ protection: Use of xenon is described. Xenon is used as an organ and/or tissue and/or cell protectant in the manufacture of a pharmaceutical for the protection from injury of organs and/or tissue and/or cells that express HIF.... Agent: Elmore Patent Law Group, PC
20090252815 - Pulverulent mixtures containing hydrogen peroxide and hydrophobized silicon dioxide: The present invention is directed to pulverulent mixtures comprising hydrogen peroxide and hydrophobized, pyrogenically prepared silicon dioxide powder, preferably with a methanol wettability of at least 40. The pulverulent mixtures exhibit good storage stability and can be used for the controlled release of hydrogen peroxide and/or oxygen. The invention also... Agent: Law Office Of Michael A. Sanzo, LLC
20090252816 - Inhalable gaseous medicament based on xenon and nitrous oxide: The invention concerns the use of a gaseous mixture containing gas xenon and gas nitrous oxide, and advantageously oxygen, for making all or part of an inhalable medicine for preventing or treating neurointoxication in a human. The xenon/nitrous oxide mixture of the invention acts on one or more cerebral receptors... Agent: Air Liquide Intellectual Property
20090252818 - Curcuma longa (turmeric) based herbal compound formulations as dietary supplements: Herbal compound formulations using herbs curcuma longa (turmeric), ocimum sanctum (holy basil) and emblica officinalis (amla) in their natural forms and a method of packaging the same for dietary supplement as tablets, wafers, capsules and as teabags where the packaging of individual dosages and the outer packaging may use visual... Agent: Tara Chand Singhal
20090252817 - Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances: The invention relates to methods for treatment and prevention of a metabolic imbalance, including diabetes mellitus and other related diseases or disorders, using an extract from a fruit of genus Elaeis.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West10/01/2009 > patent applications in patent subcategories. categorized by USPTO classification
20090246124 - High affinity vegf-receptor antagonists: A cell-based screen is reported can be used to identify specific receptor-binding compounds in a combinatorial library of peptoids (N-alkylglycine oligomers) displayed on beads. This strategy was applied to the isolation of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)-binding peptoids, which were optimized to create lead compounds with high affinity... Agent: Fulbright & Jaworski L.l.p.
20090246123 - Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin: Pharmaceutical gels and methods for delivering a therapeutic agent to a target tissue site beneath the skin of a patient are provided, the gel being capable of adhering to the target tissue site and comprising one or more biodegradable depots containing an effective amount of the therapeutic agent. In various... Agent: Medtronic Attn: Noreen Johnson - Ip Legal Department
20090246125 - Magnetic resonance contrast media: An image enhancing agent of a form comprising an effective quantity of an image enhancing material chemically or physically bound to or encapsulated within a support comprising, preferentially, an exine coating of spores of various plants or fungi, optionally with further excipients.... Agent: Weaver Austin Villeneuve & Sampson LLP
20090246126 - Thulium-based capsule and devices for use in high dose rate brachytherapy: A capsule for high dose rate brachytherapy, wherein the capsule comprises within its interior space thulium-170, and further comprises at least one layer of a radiation emission modifying metal (e.g., gold), wherein said layer is provided either internally within the capsule or on the outer surface thereof.... Agent: Nixon & Vanderhye, Pc
20090246127 - Targeting agents for molecular imaging: This invention discloses a method of synthesizing targeting contrast agents for molecular imaging and targeting diagnosis and therapy, targeting contrast agents and targeting therapeutic agents and the use thereof.... Agent: Philips Intellectual Property & Standards
20090246128 - Composition and method for detection of pre-metastatic sites: A radio-immunoconjugate for diagnosis and treatment of cancer or metastasis and development of metastasis inhibitory formulations using the same is provided. Also, a radio-immunoconjugate is used as a material indicating a metastatic cancer that has antibody marked with any lanthanum radionuclide and/or gamma, beta or alpha ray emitting radioisotopes targeting... Agent: Bardmesser Law Group, P.c.
20090246129 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Goodwin Procter LLP Attn: Patent Administrator
20090246130 - Methods and compositions for f-18 labeling of proteins, peptides and other molecules: The present application discloses compositions and methods of synthesis and use of 18F or 19F labeled molecules of use in PET or MRI imaging. The labeled molecules may be peptides or proteins, although other types of molecules may be labeled. Preferably, the 18F or 19F is conjugated to a targeting... Agent: Immunomedics, Inc.
20090246131 - Production and use of novel peptide-based agents for use with bi-specific antibodies: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred... Agent: Immunomedics, Inc.
20090246133 - Methods and compositions related to internalizing rgd peptides: Disclosed are compositions and methods useful for targeting tissue undergoing angiogenesis or to cells or tissue expressing αv integrins. The compositions and methods are based on peptide sequences that selectively bind to and home to tissue undergoing angiogenesis or to cells or tissue expressing αv integrins in animals. The disclosed... Agent: Patent Correspondence Arnall Golden Gregory LLP
20090246132 - Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof: The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20090246134 - Compositions and methods for modulating gated ion channels: The present invention is directed toward radiolabelled ASIC imaging agents, as well as metabolites of ASIC antagonists. These compounds are useful for the diagnosis and treatment of diseases and disorders related to the activity of gated ion channels.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000
20090246135 - Diagnostic agent: A diagnostic agent for being sprinkled to the inner wall of a gastrointestine in endoscopic observation, comprising an acidic aqueous solution of pH 1 to 5 containing a colorant and also containing at least one acid selected from the group consisting of a carboxylic acid, hydrochloric acid, sulfuric acid and... Agent: Buchanan, Ingersoll & Rooney Pc
20090246136 - Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration: The present invention relates to the identification of miRNAs that are involved in the process of neuromuscular synaptic maintenance and regeneration following injury or disease. Modulation of these miRNAs is proposed as treatment for spinal cord injury and neurodegenerative disease.... Agent: Cooley Godward Kronish LLP Attn: Patent Group
20090246137 - Pyridyl derivatives as cftr modulators: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Inc.
20090246139 - Efficient methods to isolate effectors of proteins involved in olfactory or chemosensory pathways and efficient methods to use these effectors to alter organism olfaction, chemosensation, or behavior: This invention provides methods and compositions for identifying effectors, binding partners, or other molecules that interact with the proteins involved in the chemosensory pathway; examples of proteins involved in the olfactory pathway include odorant binding proteins (OBPs), sensory appendage proteins (SAPs), orthologs of the Drosophila melanogaster Takeout protein (TOLs), odorant... Agent: David R Preston & Associates Apc
20090246138 - Method of imaging metabolic function: A contrast imaging method e.g. of the T2* weighted “BOLD” type is adapted by use together with an oxygen challenge to provide imaging for the assessment of the metabolic responses of tissue over a period of time the method utilizing three components, oxygen, deoxyhaemoglobin, and oxyhaemoglobin together with time, to... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group
20090246140 - Methods for identifying and targeting autonomic brain regions: Disclosed herein are methods for identifying and targeting autonomic and autonomic-related brain regions. In one embodiment, a method of identifying a brain region in a patient comprises administering to the patient a targeting agent that activates or inhibits a brain region and imaging the brain region.... Agent: Dorsey & Whitney, LLP Intellectual Property Department
20090246143 - Non-radioactive traceable metal isotope-enriched nanoparticles and method of their use for determining biodistribution: Composition of non-radioactive traceable metal isotope-enriched nanoparticles, and methods of their use for determining in-vivo biodistribution are provided. The methods comprise the steps of: (a) introducing the nanoparticles into the biological material, wherein the nanoparticles comprise at least one inorganic core, and the inorganic core comprises at least two metal... Agent: General Electric Company Global Research
20090246144 - System and method for indirectly measuring calcium ion efflux: A system and method for indirectly measuring calcium ion efflux from a cell of a subject by using manganese ions as a surrogate marker for calcium is disclosed. Manganese ion efflux is measured with a MEMRI T1-mapping method while the calcium-sodium exchanger is inhibited.... Agent: Gardner Groff Greenwald & Villanueva. Pc
20090246145 - Imaging correlates of neurogenesis with mri: This invention provides a method for treating a mammalian subject afflicted with a disorder associated with reduced neurogenesis in the subject's hippocampal dentate gyrus which comprises administering to the subject a therapeutically effective amount of a compound which increases cerebral blood volume in the subject's hippocampal dentate gyrus by a... Agent: Cooper & Dunham, LLP
20090246141 - Higher fatty acid triester and amide derivative having diethylenetriamine-type metal chelate structure: A compound having superior solubility and suitable for a liposome contrast medium selective for a lesion such as vascular diseases is provided which is represented by the following general formula (I) wherein R1 to R3 represent an alkyl group or alkenyl group; X1 and X2 represent a single bond, —O—,... Agent: Sughrue Mion, Pllc
20090246142 - Triggered self-assembly of nanoparticles in vivo: The present invention provides triggered self-assembly nanosystems. Such nanosystems comprise a population of triggered self-assembly conjugates, each conjugate comprising one or more monomeric units and one or more complementary binding moieties. In some embodiments, inventive nanosystems and conjugates can be used to treat and/or diagnose a disease, disorder, and/or condition.... Agent: Choate, Hall & Stewart LLP
20090246146 - Halides in the treatment of pathogenic infection: The present invention relates to the use of halides and halide salts for the treatment of microbial infections, including those caused by bacteria, fungi and viruses. The present invention takes advantage of endogenous immune function and augments this system using a non-toxic and inexpensive reagent that can be delivered to... Agent: Fulbright & Jaworski L.l.p.
20090246147 - Delivery of antipsychotics through an inhalation route: The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a method aspect of the present invention, an antipsychotic is delivered to a patient through an inhalation route. The method comprises: a) heating... Agent: Swanson & Bratschun, L.l.c
20090246149 - Medicinal aerosol formulations: Use of particulate bulking agents having an extremely small mass median diameter of less than one micron, preferably less than 300 nm, in pharmaceutical aerosol formulations comprising a suspension of drug particles in a propellant. Examples of bulking agents include ascorbic acid, saccharides, polysaccharides, amino acids, organic and inorganic salts,... Agent: 3m Innovative Properties Company
20090246148 - Medicinal aerosols and methods of delivery thereof: e
20090246150 - Antimicrobial composition: The present invention relates to novel antimicrobial composition comprising a peptide which can be obtained from the milk protein casein or chemically synthesised or produced by recombinant DNA technology and a divalent cation.... Agent: Bozicevic, Field & Francis LLP
20090246151 - Processes of making oral compositions containing gel networks: The present invention is directed towards a process for making oral compositions comprising gel networks. The gel networks are formed from a fatty amphiphile dispersion and swelling surfactant. The fatty amphiphile dispersion comprises one or more fatty amphiphiles, one or more dispersing surfactants, and one or more solvents. A gel... Agent: The Procter & Gamble Company Global Legal Department - Ip
20090246155 - Compositions and methods for personal care: Systems and methods for delivering personal care materials. Crystalline polymeric systems, referred to as CYC carriers, are associated with the cosmetic materials, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which... Agent: Bell & Associates
20090246153 - Cosmetic compositions for the inhibition of reactive oxygen species: A composition and method having anti-aging properties is provided. The composition comprises an arNOX inhibitory agent present in a natural plant extract and is useful topically as a cosmetic. The symptoms of aging including lines, wrinkles, hyperpigmentation, dehydration, loss of elasticity, angioma, dryness, itching, telangietasias, actinic purpura, seborrheic keratoses and... Agent: Dorsey & Whitney LLP Intellectual Property Department
20090246152 - Naractin compositions for the inhibition of reactive oxygen species: The invention relates to agents for sequestering serum aging factors, and methods for using the same. More particularly, the invention relates to agents termed herein “Naractin” to denote any one of several naturally-occurring arNOX inhibitors either present in N. tazetta powder or capable of augmenting N. tazetta powder to an... Agent: Dorsey & Whitney LLP Intellectual Property Department
20090246156 - Anti-acne sunscreen composition: The present invention is directed to compositions for anti-acne sunscreen. The sunscreen composition has the unique ability to treat and prevent acne in addition to screen both UVA and UVB radiation. In particular, the sunscreen composition includes a sunscreen base, at least one UVA deactivator, at least one UVB deactivator,... Agent: Husch Blackwell Sanders LLP
20090246157 - Method of quenching electronic excitation of chromophore-containing organic molecules in photoactive compositions: wherein A and B are the same or different and are selected from the group consisting of oxygen, amino and sulfur; R1 and R3 are the same or different and are selected from the group consisting of C1-C30 alkyl, C2-C30 alkylene, C2-C30 alkyne, C3-C8 cycloalkyl, C1-C30 substituted alkylene, C2-C30 substituted... Agent: Marshall, Gerstein & Borun LLP
20090246158 - Antioxidants: The present invention relates to the use of compounds of the formula (I) where R stands for [lacuna] with radicals defined in the description, as antioxidants, to corresponding novel compounds and compositions, and to corresponding processes for the preparation of compounds and compositions.... Agent: Millen, White, Zelano & Branigan, P.c.
20090246159 - Composition and process for treating keratinous substrates with at least two immiscible cosmetic compositions: A process for treating a keratinous substrate involving: (a) providing at least a first composition having a continuous phase whose major ingredient has a solubility parameter corresponding to δ; (b) providing at least a second composition having a continuous phase whose major ingredient has a solubility parameter corresponding to δ′;... Agent: Lerner, David, Littenberg, Krumholz & Mentlik
20090246160 - Oxidizing aqueous dispersion for treating keratin fibers comprising at least one nonionic amphiphilic hydrophobic compound: The subject of the present disclosure is a composition for treating keratin fibers comprising, in a cosmetically acceptable medium, at least one oxidizing agent; at least one nonionic amphiphilic hydrophobic compound which is solid at ambient temperature; and, optionally, at least one hydrophilic surfactant; wherein the weight ratio of the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20090246163 - Anti-static skin products and method: An aqueous or non-aqueous preparation comprising cationic agents to neutralize a negative charge thereby relieving tension in the skin and preventing moisture from escaping. It relieves static-tension in the skin thereby reducing the distance between the pores. The difference between the Present Invention and other water based skin conditioners is... Agent: Stanley H. Kremen
20090246161 - Cationic capped dimer acid polyesters in personal care applications: The present invention is directed to a series of cationic polyester compounds made from the reaction of (a) a difunctional hydroxy compound, specifically polyoxyalkylene glycols, (b) a difunctional carboxylic acid, specifically dimer acid and hydrogenated dimer acid, and (c) a capping cationic, hydroxyl containing compound which only contains one hydroxyl... Agent: Anthony J. O'lenick, Jr.
20090246164 - Tissue adhesion: A method of adhering biological tissue that includes applying a bio-degradable adhesive to the tissue. The adhesive includes a moisture-curable, isocyanate-functional component prepared by reacting (a) a multi-functional isocyanate component and (b) a multi-functional active hydrogen component that includes at least 30% by weight, based upon the total weight of... Agent: Bartony & Hare, LLP
20090246165 - Disinfectant with quarternary ammonium polymer and copolymers: An alcohol-soluble, water-insoluble, disinfectant composition and a method of using the same for disinfecting and for providing a prolonged antimicrobial property to a variety of surfaces, including skin. The composition comprises an antimicrobial polymer that is capable of imparting an antimicrobial property to a surface without the use of a... Agent: Elman Technology Law, P.c.
20090246166 - Pearl like polyvinyl alcohol particles, production process thereof and temporary vascular embolic agent: The embodiments provide a temporary vascular embolic agent temporarily blocking the blood vessel in vivo, having appropriate dissolution speed suitable for use in the blood vessel in which blood flow is fast and being more superior in the passing property of a catheter and the controllability of embolization time than... Agent: Rahman Llc
20090246167 - Stimuli-responsive systems for controlled drug delivery: A method of delivering a therapeutic agent by providing a cross-linked polymer encapsulating the therapeutic agent to a site in a patient. The degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades.... Agent: Choate, Hall & Stewart LLP
20090246162 - Treatment of chronic progressive heart failure: The invention provides a method for treating or preventing heart failure in a subject, which includes administering to the subject in need thereof a therapeutically effective amount of a Poloxamer (e.g., Poloxamer 188).... Agent: Honigman Miller Schwartz & Cohn LLP
20090246168 - Antitumoral treatments: The present invention relates to combinations of aplidine or aplidine analogues with other antitumoral agents, and the use of these combinations in the treatment of cancer, in particular in the treatment of lung cancer, breast cancer, colon cancer, prostate cancer, renal cancer, melanoma, multiple myeloma, leukemia and lymphoma.... Agent: King & Spalding
20090246169 - Indolopyridines as eg5 kinesin modulators: Compounds of a certain formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.... Agent: Millen, White, Zelano & Branigan, P.c.
20090246170 - Therapeutic agent for alzheimer's disease: The present invention provides novel therapeutic methods and agents for treating Alzheimer's disease. Specifically, the present invention relates to anti-inflammatory cytokines, anti-inflammatory cytokine genes, negative-strand RNA viral vectors carrying an anti-inflammatory cytokine gene, which are used for treating Alzheimer's disease or developing therapeutic agents for Alzheimer's disease. The present invention... Agent: Clark & Elbing LLP
20090246171 - Automatic system for dose control in treating hepatitis c using infusion pumps: According to one embodiment, a method of controlling a plurality of treatment dosages for Hepatitis C includes: setting a first dosage level to cause a viral load of a subject user to reduce at a rate over time; determining, after setting the first dosage level, if the rate of the... Agent: Foley & Lardner
20090246173 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.
20090246174 - Treatment for cutaneous t cell lymphoma: The present invention provides method for treating a patient with cutaneous T cell lymphoma (CTCL). Generally, the methods include administering to the patient an IRM compound in an amount effective to ameliorate at least one symptom or clinical sign of CTCL. In some embodiments, the methods also include administering to... Agent: 3m Innovative Properties Company
20090246176 - Method for treating diabetes mellitus, obesity, chronic fatigue, aging, and other medical conditions by utilizing modified virus virions to insert messenger ribonucleic acid molecules into cells: The common link between diabetes mellitus, obesity, chronic fatigue and even aging may be related to deficiencies involving a body's metabolism of glucose and the ability to optimally conduct the necessary biologic processes of aerobic respiration. Utilizing a modified form of virus to deliver to cells in the body the... Agent: Lane B. Scheiber
20090246175 - Therapeutic use of scin, a staphylococcal complement inhibitor in inflammatory diseases: The present invention relates to the use of the staphylococcal complement inhibitor (SCIN) or a homologue thereof, or a derivative or a fragment of SCIN or the SCIN homologue for the preparation of a medicament for intervening with C3 and C5 convertases. The medicament is in particular intended for inhibiting... Agent: Bozicevic, Field & Francis LLP
20090246183 - Enos mutations useful for gene therapy and therapeutic screening: The present invention relates to new NOS variants or mutants which contain structural alterations in the site of Akt dependent phosphorylation. The altered NOS proteins or peptides, especially the human eNOS proteins or peptides, Akt proteins or polypeptides and their encoding nucleic acid molecules are useful as gene therapy agents... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group
20090246182 - Method for culturing cells derived from the adipose tissue and uses thereof: The invention concerns a method for culturing cells derived from the adipose tissue and in particular the stromal vascular fraction (SVF) to induce formation of cardiomyocytes, the use of the cells obtained by said culture method to reconstitute an ischemized cardiac zone, in particular following an infarction, as well as... Agent: Alston & Bird LLP
20090246177 - Megasphaera elsdenii strain and its uses: This invention relates to a novel strain of Megasphaera elsdenii and its uses. This invention further relates to preparations and methods incorporating such strain. This invention also relates to feedstuffs for ruminants and a preparation and method for the prevention and treatment of lactic acidosis in ruminants. This invention even... Agent: Mirick, O'connell, Demallie & Lougee, LLP
20090246184 - Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same: The disclosure relates to a solid glass matrix of polysaccharide, saccharides and polyols as delivery vehicle for preservation and post gastric administration of a probiotic. The delivery vehicle is capable of releasing the probiotic at their site of action. The present invention further includes methods of making and using the... Agent: Moore & Van Allen Pllc
20090246178 - Cd56 positive human adult pancreatic endocrine progenitor cells: The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stems cells having a high propensity to differentiate into insulin producing cells or into insulin producing cell aggregates.... Agent: Morrison & Foerster LLP
20090246180 - Hypoxia inducing factors and uses thereof for inducing angiogenesis and improving muscular functions: This invention provides HIF-3α nucleic acid and sequences. Also provided are methods for using HIF-3α nucleic acids, proteins, fragments, antibodies, probes, and cells, to characterize HIF-3α, modulate HIF-3α cellular levels, induce angiogenesis, improve muscular function, and treat coronary and cardiac diseases in mammals.... Agent: Myers Bigel Sibley & Sajovec
20090246179 - Method of treating myocardial injury: A method of treating a myocardial injury of a subject includes administering a population of at least one of mesenchymal stem cells (MSCs), multipotent adult progenitor cells (MAPCs), embryonic stem cells (ESCs), induced pluripotent stem cells (iPSs), which have down-regulated expression of disabled-2 (Dab2), to the subject.... Agent: Tarolli, Sundheim, Covell & Tummino L.l.p.
20090246181 - Therapeutic composition for atopic dermatitis: A novel type of therapeutic agent, human mesenchymal stem cells, and a composition containing the same for the treatment of atopic dermatitis is disclosed. A method for the treatment of atopic dermatitis in patient is also disclosed.... Agent: Millen, White, Zelano & Branigan, P.c.
20090246186 - Agent for improving nervous system cell functions: An agent for improving a neural cell function containing reduced coenzyme Q as an active ingredient, more specifically, an agent for activating neural cells and an agent for protecting neural cells, is useful, and can be used for the improvement or prophylaxis of central neurological diseases or neuropathy symptoms derived... Agent: Sughrue Mion, Pllc
20090246185 - Cardiac dysfunction-ameliorating agent or cardiac function-maintaining agent: An object of the present invention is to provide a highly safe oral composition superior in a cardiac dysfunction-ameliorating or cardiac function-maintaining action. The present inventors have conducted intensive studies in an attempt to solve the aforementioned problems and found that use of, particularly, reduced coenzyme Q10 from among highly... Agent: Sughrue Mion, Pllc
20090246187 - Process for concentration of a polypeptide: The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such a concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection.... Agent: Foley And Lardner LLP Suite 500
20090246188 - Method for production of a bioengineered form of tissue plasminogen activator: The present invention relates to the recombinant method used for the production of soluble form of human tissue plasminogen activator variant. In this variant the threonine at position 103 of the endogenous tissue plasminogen activator is replaced by an asparagine leading to a new glycosylation site. At position 117 of... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20090246192 - 1d05 pcsk9 antagonists: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host... Agent: Merck And Co., Inc
20090246190 - Anti-vegf antibody: An antibody is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain that comprises CDR regions that are substantially identical to the heavy chain CDR regions of a selected antibody and b) a light chain variable domain that comprises CDR regions that are substantially identical to... Agent: Bozicevic, Field & Francis LLP
20090246193 - Inactivating organisms using carbon dioxide at or near its supercritical pressure and temperature conditions: Whole organisms are inactivated by at least a factor of 106 using carbon dioxide at or near its supercritical pressure and temperature conditions.... Agent: Welsh & Flaxman Llc
20090246189 - Methods for promoting neurite outgrowth and survival of dopaminergic neurons: The present invention relates generally to methods for promoting regeneration, outgrowth and survival of dopaminergic neurons comprising contacting said dopaminergic neurons with an effective amount of a composition comprising an Sp35 antagonist. Additionally, the invention is related generally to methods of treating various diseases, disorders or injuries associated with dopaminergic... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.
20090246191 - Preparation of purified covalently cross-linked abeta oligomers and uses thereof: The present invention provides a method of purifying cross-linked oligomers. The purified cross-linked oligomers are useful as immunogen for generating and isolating cross-linked oligomer reactive antibodies. The cross-linked oligomer reactive antibodies are useful for detecting amyloid deposition and for diagnosing and treating diseases and conditions associated with amyloid deposition.... Agent: Morgan Lewis & Bockius LLP
20090246195 - Anti-cd19 antibody therapy for transplantation: The invention relates to immunotherapeutic compositions and methods for the treatment and prevention of GVHD, humoral rejection, and post-transplantation lymphoproliferative disorder in human subjects using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or... Agent: Ropes & Gray LLP
20090246197 - Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc): The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount... Agent: Hoffmann-la Roche Inc. Patent Law Department
20090246196 - Combined targeted therapy for the treatment of proliferative disease: A method of treating an individual comprising: evaluating the disease state of said individual through quantitative and/or qualitative assays; administering in amounts sufficient to treat said disease at least three agents wherein at least one agent is an inhibitor of the human epidermal receptor pathway, at least one agent is... Agent: Conley Rose, P.c. David A. Rose
20090246194 - Erythropoietin analog-igg fusion proteins: Erythropoietin analog-human IgG fusion protein (EPOa-IgG) fusion protein and methods of making and using the fusion protein.... Agent: Gtc Biotherapeutics, Inc. C/o Wolf, Greenfield & Sacks, P.c.
20090246198 - Mapk/erk kinase inhibitors and methods of use thereof: y
20090246199 - Therapeutic methods for inhibiting tumor growth with dll4 antagonists: Disclosed is a therapeutic method for inhibiting development or growth of tumors that are resistant to the blockade of delta-like ligand 4 (Dll4), or vascular endothelial growth factor (VEGF), or to other therapeutic agents, by administering the combination of Dll4 antagonist and VEGF antagonist. The combined administration of these two... Agent: Regeneron Pharmaceuticals, Inc
20090246200 - Anthrax carbohydrates, synthesis and uses thereof: The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies.... Agent: Mueting, Raasch & Gebhardt, P.a.
20090246202 - Human endokine alpha and methods of use: The present invention concerns a novel member of the tumor necrosis factor (TNF) family of cytokines. In particular, isolated nucleic acid molecules are provided encoding the endokine alpha protein. Endokine alpha polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.
20090246201 - Substances: The present invention provides a homologue to heparanase which is present in three splice variants.... Agent: Klauber & Jackson
20090246203 - Method for immunoadsorption by means of autoanitgens: The invention relates to a novel method for immunoadsorption therapy of human autoimmune diseases by means of immobilized or fixed autoantigens.... Agent: Connolly Bove Lodge & Hutz, LLP
20090246204 - Use of a cd28 binding substance for making a pharmaceutical composition: The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimicry compound hereto for making a pharmaceutical composition for the induction and/or multiplication of regulatory T cells.... Agent: Mayer & Williams Pc
20090246205 - Inhibition of macrophage-stimulating protein receptor (ron): The present invention relates to methods for treatment of tumors and other diseases in a mammal comprising administration of antibodies specific for Macrophage-Stimulating Protein Receptor (“MSP-R” or “RON”). The present invention further provides for compositions comprising antibodies or antibody fragments specific for RON, including human antibodies, that inhibit RON activation.... Agent: Eli Lilly & Company
20090246206 - Bispecific binding agents for modulating biological activity: Methods for improving the specific binding ability of bispecific binding compositions are described. The bispecific binding compositions are able to target cells by a high affinity targeting domain to a target cell surface marker and a low affinity binding domain that binds specifically to a second cell surface marker, wherein... Agent: Townsend And Townsend And Crew, LLP
20090246207 - Calf biologic anti-scour supplement (cbas): A composition for prevention digestive infection in a ruminant infant is disclosed. The composition consists of: a predetermined amount of yolk immunoglobulin (IgY) for a target bacteria; a predetermined amount of a plurality of hormones and a predetermined amount of a plurality of proteins, wherein said plurality of hormones comprises... Agent: Barry Choobin
20090246209 - Gnrh analogues for treatment of urinary incontinence: The use of at least one GnRH analogue for the preparation of a medicament for the prevention and/or treatment of side effects of ovarectomy or symptoms associated with reproductive senescence in female mammals, in particular urinary incontinence, hot flushes, and skin/hair changes are disclosed.... Agent: Joyce Von Natzmer Pequignot + Myers Llc
20090246210 - Il-1beta binding antibodies and binding fragments thereof: An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 26 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease. IL-1β binding antibodies or IL-1β... Agent: K&l Gates LLP
20090246208 - Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis: Methods for preventing and treating osteolysis, cancer metastasis and bone loss associated with cancer metastasis by administering an M-CSF-antagonist in combination with a therapeutic agent to a subject are provided.... Agent: Marshall, Gerstein & Borun LLP
20090246211 - Molecular constructs suitable for targeted conjugates: t
20090246212 - Development of method for screening for drug capable of improving production of regulatory t cells and method for producing regulatory t cells using immunosuppressive macrolide antibiotic: The present invention also provides a method of producing regulatory T cells, comprising culturing CD4+ T cells having a naïve phenotype in the presence of a rapamycin compound to obtain regulatory T cells. The regulatory T cell produced by the method can be used as an immunomodulator for the prophylaxis... Agent: Leydig Voit & Mayer, Ltd
20090246214 - Fusion proteins containing recombinant cytotoxic rnases: Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. The immunotoxins may be... Agent: Rossi, Kimms & Mcdowell LLP.
20090246213 - Vaccine comprising a polynucleotide encoding an antigen recognized by a cd4+ helper t-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a cd8+ ctl: The present invention relates to a DNA vaccine for developing tumor-specific immunity. Specifically, the invention relates to a DNA vaccine comprising antigens recognized by CD4+ helper T cells and CD8+ cytotoxic T cells, respectively. Preferably, the antigen recognized by CD4+ helper T cells is a molecule identified by the SEREX... Agent: Townsend And Townsend And Crew, LLP
20090246215 - Amyloid beta1-6 antigen arrays: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an Aβ1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least... Agent: Volpe And Koenig, P.c.
20090246216 - Novel attenuated poliovirus: A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5′ non-translated genomic region and inactivating the native cre element located in the coding region of 2C (mono-crePV). The stably attenuated poliovirus replicates in a neuroblastoma model (Neuro-2aCD155... Agent: Kenyon & Kenyon LLP
20090246217 - Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity: In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject, and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with this peptide, a pharmaceutical composition... Agent: Mccarthy Tetrault LLP
20090246219 - Novel surface exposed haemophilus influenzae protein (protein e; pe): The present invention relates to a surface exposed protein (protein E; pE), a virulence factor, which can be detected in Haemophilus influenzae, having an amino acid sequence as described in SEQ ID NO 1, an immunogenic fragment of said surface exposed protein, and a recombinant immunogenic protein (pE (A)) or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20090246218 - S. aureus fibrinogen binding protein gene: The isolation of genes and proteins from Staphylococcus aureus is provided, and the nucleic acids coding for specific regions of the S. aureus protein are described. The nucleic acids encode proteins that can be useful as vaccines or in pharmaceutical compositions for application to prevent infection, promotion of wound healing,... Agent: Stites & Harbison Pllc
20090246220 - Constructs for enhancing immune responses: Chimeric protein constructs including a herpesvirus glycoprotein D (gD) and a heterologous polypeptide that interact with herpes virus entry mediator (HVEM) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided.... Agent: Banner & Witcoff, Ltd.
20090246221 - Immunomodulatory agents and methods of use: An antisense oligonucleotide compound, composition, vaccine and methods for treating a variety of conditions characterized by up-regulation of IL-10 in a mammalian subject are disclosed. The compound (i) is composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of... Agent: King & Spalding LLP
20090246222 - Live attenuated bordetella strains as a single dose vaccine against whooping cough: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of... Agent: Birch Stewart Kolasch & Birch
20090246223 - Inactivated chimeric vaccines and related methods of use: Embodiments of the present invention generally provide an inactivated chimeric virus vaccine and/or immunogenic composition for the treatment or prevention of viral infection. Further, various other embodiments of the present invention generally relate to methods of preventing and treating virus infection in such animals with the inactivated vaccine and/or immunogenic... Agent: Intervet/schering-plough Animal Health
20090246224 - Vaccine: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482
20090246225 - Methods of producing influenza vaccine compositions: Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided.... Agent: Medimmune, Llc Jonathan Klein-evans
20090246226 - Avian vaccines possessing a positive marker gene: The present invention provides a poultry vaccine containing a positive marker gene. More specifically, recombinant turkey herpesvirus modified by the presence of an extraneous antigen gene that may be used as a positive marker to identify and track vaccinated animals is provided. When inoculated into host animals, a poultry vaccine... Agent: Kratz, Quintos & Hanson, LLP
20090246227 - Methods of use for hsv-1 and hsv-2 vaccines: This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated... Agent: Pearl Cohen Zedek Latzer, LLP
20090246228 - Moraxella catarrhalis proteins: Novel antigens of B. catarrhalis are provided, together with their use in vaccines as well as methods of diagnosing and/or detection.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.
20090246229 - Subunit vaccine of pasteurella multocida in veterinary uses: The present invention declaims the use of Pasteurella lipoprotein E (PlpE) as a subunit vaccine and the use of vaccines containing PlpE to protect animals from diseases caused by P. multocida. The results of vaccination and challenge experiments showed that mice and chickens immunized with PlpE were completely protected animals... Agent: Pai Patent & Trademark Law Firm
20090246230 - Compositions and methods for inducing tumor resistance: The invention provides a combined whole cell tumor vaccine for inducing tumor resistance in patients and treating cancer.... Agent: Foley And Lardner LLP Suite 500
20090246231 - Formulations containing borojo: The present invention relates to a cosmetic and skin care formulation comprising: borojo; and at least one humectant; and at least one emollient. The present invention also provides for a dietary and nutritional supplement comprising: borojo; at least one mineral; at least one vitamin and at least one protein.... Agent: Dan M. Delarosa
20090246232 - Pharmaceutical composition: Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.... Agent: Foley And Lardner LLP Suite 500
20090246233 - Treatment of gastroparesis and nonulcer dyspepsia with gabab agonists: The present invention relates to formulations comprising a therapeutically effective amount of baclofen or (R)-baclofen, or pharmaceutically acceptable salts thereof, and methods of their use. The present formulations and methods are designed to release a therapeutic amount of baclofen in a manner that maximizes its therapeutic effect. The methods and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20090246234 - therapeutic treatment using niacin for skin disorders: Niacin and/or niacinamides are incorporated with liposomes in therapeutic compositions for topical application to prevent or alleviate the conditions and symptoms of skin aging and other histological disorders. In particular, niacin and/or niacinamides are combined with liposomes to increase the penetration of the niacin and/or niacinamides into the deep epidermis... Agent: Glenn L. Webb Glenn L. Webb P.c.
20090246236 - Hair care compositions comprising sucrose polyesters: A hair care composition having a conditioning active comprising a sucrose polyester having a melting point greater than about 30° C., an IBAR greater than about 5, an IV of about 3 to about 70, and an aqueous carrier, and may further comprise optional ingredients including but not limited to,... Agent: The Procter & Gamble Company Global Legal Department - Ip
20090246235 - Polyamide porous spherical particle: Polyamide porous spherical particles having a number-average particle diameter of 2 to 30 μm, a BET specific surface area of 100 to 80,000 m2/kg, and a ratio of a volume-average particle diameter to the number-average particle diameter in the range of 1.52 to 2.50 is reduced in luminous reflectance.... Agent: Nixon Peabody, LLP
20090246238 - Reinforced absorbable multilayered hemostatic wound dressing: The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and/or fibrinogen.... Agent: Philip S. Johnson Johnson & Johnson
20090246239 - Insect growth regulating composition: A microencapsulated insect growth regulating composition comprising an insect growth regulation active ingredient in a wall formed of polyurethane or polyurea, having an average particle diameter of 1 to 40 μm, a wall thickness of 0.005 to 0.5 μm, a ratio of a wall thickness/an average particle diameter of 0.0003... Agent: Sughrue Mion, Pllc
20090246240 - Dry bactericidal nonwoven wipe: A dry bactericidal wipe that provides a greater than 99% reduction in bacterium including methicillin resistant Staphylococcus aureus (MRSA), Staphylococcus aureus, and Klebsiella pneumoniae. The dry bactericidal wipe comprises a nonwoven formed primarily of hydrophilic fibers and a binder distributed throughout the hydrophilic fibers in an amount effective to maintain... Agent: Womble Carlyle Sandridge & Rice, Pllc
20090246241 - Animal pest repellant device: An article of manufacture, comprising: an animal repellant dispersed over an artificial plant structure. The artificial plant structure may be a whole artificial plant or an artificial plant portion. The invention is also an article of manufacture comprising a band, wherein the band has an animal repellant or insect repellent... Agent: Gearhart Law, Llc
20090246242 - Method and device for protecting tobacco: A method for protecting tobacco from, during, comprises the step of covering the tobacco with a material, preferably a net, which has a protective activity against the harmful organisms.... Agent: Connolly Bove Lodge & Hutz, LLP
20090246243 - Carbonaceous protective multifunctional coatings: The present invention relates to Diamond-like Carbon (DLC) coatings on metal substrates and methods of making the same. The invention particularly relates, in a preferred embodiment, to a metallic substrate such as stainless steel or Ti alloy having a silicon material (such as an organosilicone, silicon nitride, silicon carbide or... Agent: Medtronic, Inc.
20090246248 - Coating compositions having improved performance: The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second substrate-binding domain having binding affinity for a target molecule, and the target molecule. In some embodiments, the first and second substrate-binding... Agent: Laura L.kiefer Affinergy, Inc.
20090246249 - Coating compositions having improved performance: The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second substrate-binding domain having binding affinity for a target molecule, and the target molecule. In some embodiments, the first and second substrate-binding... Agent: Laura L.kiefer Affinergy, Inc.
20090246250 - Coating compositions having improved performance: The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second substrate-binding domain having binding affinity for a target molecule, and the target molecule. In some embodiments, the first and second substrate-binding... Agent: Laura L.kiefer Affinergy, Inc.
20090246251 - Coating compositions having improved performance: The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second substrate-binding domain having binding affinity for a target molecule, and the target molecule. In some embodiments, the first and second substrate-binding... Agent: Laura L.kiefer Affinergy, Inc.
20090246247 - Composite enterocystoplasty: The present invention relates to methods for tissue augmentation or regeneration. More specifically, the present invention provides for a composite enterocystoplasty procedure using a biocompatible scaffold and minced autologous tissue for implantation in a mammalian bladder.... Agent: Philip S. Johnson Johnson & Johnson
20090246244 - Malleable multi-component implants and materials therefor: Described are implantable, malleable medical materials comprising mineral particles, insoluble collagen fibers, and a gel-forming polysaccharide component and/or another added gel-former. The malleable medical materials can be used treat bone or other tissue defects in patients, including in conjunction with biologically active factors such as osteogenic proteins. Also described are... Agent: Medtronic Attn: Noreen Johnson - Ip Legal Department
20090246246 - Processes for relieving blocked vessels and products thereby: Select microbials, microbiologicals, biologics and related naturally occurring or engineered microbial solutions supplement existing device modalities. Likewise, librarying and mapping processes are disclosed by which novel enhanced processes for relieving blocked vessels can be discovered, generated or improved for intravascular usages.... Agent: Luce, Forward, Hamilton & Scripps LLP
20090246245 - Subcutaneous implants releasing an active principle over an extended period of time: Subcutaneous implants obtained by extrusion containing an active ingredient, and a hydrophilic excipient dispersed in a PLGA matrix so that the weight ratio: (Active Ingredient (AI)+Excipient (E))/PLGA is higher than 0.05 and lower than 1.... Agent: Abelmen Frayne&schab
20090246252 - Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery: The present invention provides insertable medical devices having elastic surfaces associated with bioactive agent-containing microparticulates and a coating material. Upon expansion of the elastic surfaces the microparticulates can be released to a subject.... Agent: Kagan Binder, Pllc
20090246253 - Methods of providing antioxidants to implantable medical devices: Methods of incorporating an antioxidant into a medical device including a polymer are described, and methods of packaging medical devices.... Agent: Squire, Sanders & Dempsey LLP
20090246254 - Non-hormonal vaginal contraceptive: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the... Agent: Stroock & Stroock & Lavan LLP
20090246255 - Pharmaceutical compositions for the treatment of inner ear disorders: The present invention provides compositions containing (i) a pharmaceutically active agent selected from a group consisting of an arylcycloalkyamine or a derivative, analogue or pharmaceutically active salt thereof, and (ii) a biocompatible polymer or a combination of biocompatible polymers. These compositions or medicaments containing these compositions may be used for... Agent: Kevin Farrell Pierce Atwood
20090246256 - Compositions and methods for transmucosal delivery of lofexidine: The present invention provides for compositions and methods for accelerating the rate of delivery of lofexidine to the systemic circulation by transmucosal administration through the nasal, sublingual, or buccal routes to provide rapid response in the treatment of opiate addicts, migraine, neuropathic pain, and other therapeutic indications related to lofexidine,... Agent: Frost Brown Todd, Llc
20090246257 - Wafer formulation: An orally administrable wafer is provided comprising at least one physiologically acceptable film forming agent. The wafer is formed by mixing the film-forming agent with an aqueous solution to form a gel and exposing the gel to a plurality of heating and cooling cycles. The wafer is rapidly dissolving and... Agent: Valentine A Cottrill Susan Tandan
20090246258 - Antimicrobial and odor adsorbing textile: where R is a non-hyperbranched hydrocarbon group and the hydrocarbon group has at least one linear portion. The linear portion has between 5 and 30 carbon atoms, x is a number from 1 to 10,000, h-PEI is a hyperbranched polyethyleneimine, A is an organic compound having from 1 to 4... Agent: Legal Department (m-495)
20090246262 - Easily applied field dressing for wounds: A method for treating wounds by adhering a wound dressing to a wound with a polymerizable alkyl cyanoacrylate composition, such that the wound dressing and cyanoacrylate composition seal the wound to inhibit bleeding and infection. The dressing may be in the form of a mitten. Also disclosed is injection of... Agent: Knobbe Martens Olson & Bear LLP
20090246260 - Fibrin foam and process: A fibrin wound dressing is made by mixing quantities of fibrinogen solution and thrombin solution with air. The resulting foam is very light weight, and with the proper attention to the amount of thrombin, is also sufficiently viscous to rest on a vertical surface without dripping. The wound dressing may... Agent: K&l Gates LLP
20090246261 - Fibrin foam and process for making: A fibrin wound dressing is made by mixing quantities of fibrinogen solution and thrombin solution with air. The resulting foam is very light weight, and with the proper attention to the amount of thrombin, will rest on a vertical surface without dripping. The wound dressing may also be formulated for... Agent: K&l Gates LLP
20090246263 - Adhesive preparation: A patch preparation having a backing layer and a drug layer laminated on the backing layer; wherein the drug layer contains an adhesive containing at least one compound selected from the group consisting of fentanyl and pharmaceutically acceptable salts thereof, polyisobutylene, and a silicon-containing polymer; and a mass ratio of... Agent: The Nath Law Group
20090246265 - Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists: Described herein are compositions comprising opioids, opioid antagonists and prodrugs of the same, formulations comprising opioids, opioid antagonists and prodrugs of the same, and methods of using opioids, opioid antagonists and prodrugs of the same. One embodiment described herein relates to the transdermal administration of a buprenorphine and encapsulated naltrexone... Agent: Mayer Brown LLP
20090246266 - Preparation and composition of meloxicam transdermal drug delivery system: A composition for transdermal permeation and a preparation method are disclosed. The composition including meloxicam as an active ingredient and further including at least one permeation enhancing agent selected from the group consisting of a sorbitan fatty acid derivative, a polyglyceryl fatty acid derivative, a polyethylene glycol vegetable oil ester,... Agent: Lucas & Mercanti, LLP
20090246264 - Transdermal tobacco alkaloid patch: c
20090246267 - Carnitine conjugates of adamantanamines and neramexane derivatives as dual prodrugs for various uses: This invention concerns compounds of adamantanamines and neramexane, including their pharmaceutically-acceptable salts, diesterioisomers, and formulations for treating Alzheimer's related dementias, depression, AIDS related dementias, as antivirals, inflammatory diseases such as rheumatoid arthritis, and cerebral ischemia, hyperlipidemia, and diabetes.... Agent: Technology Law, Pllc
20090246271 - Combination of ceramide and gemcitabine for inducing cell death and uses thereof in treating cancer: This invention provides a method for increasing apoptosis in a cancer cell comprising contacting the cancer cell with (a) gemcitabine and (b) C6-ceramide, sequentially or concomitantly, wherein the gemcitabine and C6-ceramide are in amounts such that the apoptosis induced by the combination of gemcitabine and C6-ceramide is greater than the... Agent: Cooper & Dunham, LLP
20090246269 - Identification and use of gprc variants in the treatment and diagnosis of parkinson's disease: The invention relates genes that are deregulated in Parkinson's disease tissues and the corresponding proteins are identified. These genes and the corresponding proteins are suitable targets for the treatment of Parkinson's disease. Also, the invention relates to compounds and their uses, particularly in the pharmaceutical industry. The invention more specifically... Agent: Nixon & Vanderhye, Pc
20090246273 - Ketorolac sublingual spray for the treatment of pain: The present invention provides for compositions and methods for accelerating the rate of delivery of ketorolac to the systemic circulation by sublingual spray administration under the tongue to provide a rapid response in the treatment of pain, especially acute pain associated with postoperative pain and migraine headache. Compositions of ketorolac... Agent: Frost Brown Todd, Llc
20090246268 - Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors: A method for preparing a stable dispersion of a camptothecin, camptothecin prodrug, or analog thereof for administration to a patient in need thereof includes preparing a solution of the camptothecin, wherein the solution has a pH which places substantially an entirety of that camptothecin in a carboxylate form. The camptothecin... Agent: King & Schickli, Pllc
20090246272 - Mda-7 proteins and methods of use thereof: This invention provides a method of generating a subtracted cDNA library of a cell comprising: a) generating a cDNA library of the cell; b) isolating double-stranded DNAs from the cDNA library; c) releasing the double-stranded cDNA inserts from the double-stranded DNAs; d) denaturing the isolated double-stranded cDNA inserts; e) hybridizing... Agent: Baker Botts L.l.p.
20090246270 - Use of iontophoresis or electrotherapy and ultrasound to deliver agents for skin rejuvenation.: The method disclosed includes the combining of iontophoresis or electrotherapy and ultrasound to deliver the appropriate chromophores to the skin for cosmetic or therapeutic treatment of the skin and skin conditions by the use of a laser, Intense Pulsed Light (IPL), a combination of laser and Radio Frequency (RF) energy,... Agent: Dennis R. Jones Ste:112
20090246274 - Pharmaceutical composition 271: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.... Agent: Hogan & Hartson LLP
20090246275 - Compositions and methods for delivery of embolics: Described herein are compositions comprising one or more embolics attached to an inert, dissolvable matrix as well as kits comprising these novel embolic formulations. Also described are methods of making and using these embolic formulations.... Agent: Robins & Pasternak
20090246276 - Pharmaceutical compositions: The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fumarate, and at least one pharmaceutically acceptable... Agent: Lovells LLP
20090246277 - Controlled release system: The invention relates to a system for controlled release of medicinally active substances, which comprises sucrose acetate isobutyrate (SAIB) and a further solvent.... Agent: Bayer Healthcare Llc
20090246278 - Use of essential oils to reduce benzodiazepine requirements during medical procedures: A method to reduce or eliminate the need for medicaments such as benzodiazepine and narcotics in noxious medical procedures, such as intravenous needle insertion, mechanical ventilation and intubation procedures, includes topically administering to the patient an effective amount of an essential oil composition including at least one essential oil selected... Agent: Amin Talati, Llc
20090246279 - Particles having hydrophobic material therein: A process for preparing particles having a hydrophobic material therein is disclosed. The process comprises providing a multiple emulsion comprising a first emulsion dispersed in a hydrophobic medium, said first emulsion comprising a hydrophobic phase dispersed in a hydrophilic phase, wherein the hydrophobic phase comprises the hydrophobic material and the... Agent: Foley And Lardner LLP Suite 500
20090246280 - Resin powder containing aluminum salt, process for production of the same, and resin composition, phosphorus adsorbent, antibacterial agent or antifungal agent comprising the same: An aluminum salt-containing resin powder of the present invention includes: at lest one matrix resin component selected from regenerated collagen, polyvinyl alcohol and carboxymethyl cellulose; and an aluminum salt. The aluminum salt is chemically bonded to the matrix resin component, and the resultant is powdered. A resin composition of the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20090246284 - O-desmethylvenlafaxine cocrystals: Disclosed herein are co-crystals comprising O-desmethylvenlafaxine and succinic acid, process for the preparation, pharmaceutical compositions, and method of treating thereof.... Agent: Cantor Colburn LLP
20090246282 - Recombinant gelatin particles for cell adhesion: The present invention relates to cell carrier particles prepared from recombinantly produced gelatins comprising at least two outer lysine residues which are separated by at least 25 percent of the total number of amino acids in the recombinant gelatin polypeptide. The invention is also directed at applications in which such... Agent: Foley And Lardner LLP Suite 500
20090246283 - Repeat sequence protein polymer nanoparticles optionally containing active agents and their preparation: A nanocomposite of a repeat sequence protein polymer, such as a copolymer of silk and elastin, is produced by Supercritical Antisolvent Precipitation with Enhanced Mass Transfer (SAS-EM). The nanocomposite may include an active agent, such as a protein or hormone, that is releasably bound to the repeat sequence protein polymer.... Agent: Jill A. Jacobson Genencor International
20090246281 - Soft steroid compositions for use in dry powder inhalers: A medicament and a method of producing a medicament are disclosed. The medicament contains a soft steroid and is suitable for administration via a dry powder inhaler.... Agent: Kenyon & Kenyon LLP
20090246285 - Monodispersed organic monolayer coated calcium-containing nanoparticles: A method for the synthesis of monodispersed, organic-monolayer coated, calcium-containing nanoparticles is presented. A biphasic liquid system comprises an aqueous phase of bare particles and an organic phase containing organic molecules with carboxylic acid end group is mixed. The carboxylic acid group binds to the surface of the calcium-containing particles... Agent: Pearl Cohen Zedek Latzer, LLP
20090246286 - Particle for medical use and process for producing the same: The present invention has solved the above problem with a particle for medical use having a layer containing a polymer compound formed on a surface of a core particle, wherein the polymer compound is a polymer comprising at least repeating units derived from an ethylenically unsaturated polymerizable monomer (a) having... Agent: Smith, Gambrell & Russell
20090246287 - Anti-allergy compositions: The present invention relates to particles of glucans, particularly oxidized cellulosed for use in medicine. The invention further discloses pharmaceutical compositions for the treatment and/or prophylaxis of diseases or disorders associated with or mediated by allergens.... Agent: Brooks Kushman P.c.
20090246288 - Taste-masking oral dosage form and method of preparing the same: The present invention provides a taste-masking oral dosage form which comprises a taste-masked microparticle and an excipient. The taste-masked microparticle comprises a taste-masked crystal containing an active pharmaceutical ingredient masked by a hydrophilic polymer and a starch. The present invention also provides a method for making the taste-masked microparticles and... Agent: Andrews Kurth LLP
20090246289 - System and method for diagnosing and managing those at risk for cardiovascular disease: A system and method for diagnosing and managing patients at risk for cardiovascular disease. The system and method provides for automating the ordering of a number of advanced tests, compiling and evaluating test results, and producing an automated report which includes recommended disease management options.... Agent: Snell & Wilmer L.l.p. (main)
20090246290 - Lipid metabolism improving agent containing hydrogen molecules: The lipid metabolism improving agent of the present invention comprises a liquid or gas containing at least hydrogen molecules. It may comprise a medium containing oxygen molecules. Further, such medium may comprise water, an aqueous solution, or a gas. The lipid metabolism improving agent has effects of suppressing body fat... Agent: Wenderoth, Lind & Ponack, L.l.p.
20090246291 - Method and compositions for treatment of cancer: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to the subject a combination of sodium meta arsenite and/or arsenic trioxide and a cytotoxic anticancer agent, such as cisplatin, adriamycin, and taxane, such as larotaxel, orataxel, tesetaxel, docetaxel or paclitaxel. The... Agent: Mcdermott Will & Emery LLP
20090246292 - Antimicrobial formulations comprising a quinone and a copper salt: An antimicrobial formulation containing a quinone, such as a benzoquinone or hydroquinone, and a copper salt. The formulation may in particular be used against staphylococci or propionibacteria, more particularly to treat skin and skin structure conditions such as acne.... Agent: Weaver Austin Villeneuve & Sampson LLP
20090246293 - Compositions and methods to control oomycete fungal pathogens: The present invention relates to compounds and the use of such compounds for increasing the efficacy of fungicides for controlling oomycete pathogen induced disease or diseases in one or more plants.... Agent: Dow Agrosciences Llc
20090246294 - Pigment mixture, and use thereof in cosmetics, food and pharmaceuticals: The invention relates to pigment mixtures comprising at least two components A and B. The inventive pigment mixtures are characterized in that component A is embodied as effect pigments while component B is embodied as coloring agents and fillers. Also disclosed is the use of said pigment mixtures in cosmetic... Agent: Millen, White, Zelano & Branigan, P.c.
20090246295 - Preparation of concentrated aqueous bromine solutions and biocidal applications thereof: A process of producing a concentrated liquid biocide formulation is described. Mixed together are (a) bromine and (b) an aqueous solution of alkali metal salt of sulfamic acid having a pH of at least about 12, in amounts such that (i) the active bromine content of the solution is at... Agent: Albemarle Corporation
20090246296 - Method of treating ischemia/reperfusion injury with nitroxyl donors: Nitroxyl donating compounds are administered prior to the onset of ischemia for the prevention and/or reduction of ischemia/reperfusion injury in subjects at risk for ischemia. Nitroxyl donors also are administered to organs to be transplanted for the prevention and/or reduction of ischemia/reperfusion injury upon reperfusion in a recipient. Nitroxyl donors... Agent: Morrison & Foerster LLP
20090246297 - Turf mold remediation: A method for treating diseased plants, such as turf and trees, includes mixing a quantity of a plant remediation composition with water and applying the plant remediation composition to the diseased plants. The plant remediation composition may include from about 30 to about 50 volume percent of a potassium silicate,... Agent: Holland & Knight LLP
20090246299 - Fat composition: m
20090246298 - Viagra: 3. Skull Cap works on the body using the volatile fixed oils, (essential oil) The main color titrated out is green, green works on the heart. In the Contraction phase the heart rests. There are seven botanical herbs in the Magistral Viagra. The synergistic effect causes the free flow of... Agent: Ceola P. Steele
20090246300 - Adaptogenic tea: A natural adaptogenic tea is prepared from adaptogens to counter adverse physical, chemical, or biological stressors and to promote t-cell activity and k-cell activity. Also, the composition is high in antioxidants and discourages free radicals. Moreover, the composition improves liver performance, resulting in improved toxin removal and improved nutrient absorption.... Agent: Delaney Ip
20090246301 - Method for treating irritable bowel syndrome and other functional gastrointestinal disorders: The invention relates to methods and compositions for the treatment of irritable bowel syndrome (IBS) and other functional gastrointestinal disorders. The methods of the invention involve the administration, in a delayed-release capsule or tablet containing a mixture of peppermint oil and chlorophyll. Other ingredients that may also be effective treatments... Agent: Jonathan D. Feuchtwang
20090246302 - Composition and method for protecting agricultural crops and/or agricultural products: The present invention provides a composition and a method for protecting agricultural crops and/or agricultural products against insects/pests. The said composition comprising an effective amount of extract obtained from Piper betle Linn. The plant material prepared in accordance with this invention is extremely effective in reducing insect populations and preventing... Agent: Edwards Angell Palmer & Dodge LLP
20090246303 - Method for reducing the effects of chemotherapy using flagellin related polypeptides: The use of flagellin and flagellin related polypeptides for reducing cancer treatment side effects in mammals is described.... Agent: Polsinelli Shughart PcPrevious industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus
RSS FEED for 20130509:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.
FreshPatents.com Support - Terms & Conditions
Results in 2.61719 seconds